Form990
Click to see attachment
Department of the Treasury
Internal Revenue Service
Return of Organization Exempt From Income Tax
Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except black lung benefit trust or private foundation)

MediumBullet The organization may have to use a copy of this return to satisfy state reporting requirements.
OMB No. 1545-0047
2011
Open to Public Inspection
A For the calendar year, or tax year beginning 01-01-2011 and ending 12-31-2011
BCheck if applicable:
CName of organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Doing Business As
 
 
Number and street (or P.O. box if mail is not delivered to street address)
GRAND CENTRAL STATION P O BOX 47
 
Room/suite
City or town, state or country, and ZIP + 4
NEW YORK, NY101634777
D Employer identification number

13-4141945
E Telephone number

G Gross receipts $ 67,216,814
F Name and address of principal officer:
Todd Sherer
GRAND CENTRAL STATION P O 4777
New York,NY101634777
I
Tax-exempt status: (   ) LeftBullet (insert no.) or
J
Website:MediumBullet
www.michaeljfox.org
H(a)
Is this a group return for
affiliates?
H(b)
Are all affiliates included?
If "No," attach a list. (see instructions)
H(c)
Group exemption number MediumBullet  
K Form of organization:
 
L Year of formation: 2000
M State of legal domicile: DE
Part I
Summary
Activities & Governance 1 Briefly describe the organization’s mission or most significant activities: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA.
2 Check this box MediumBullet
3 Number of voting members of the governing body (Part VI, line 1a)..... 3 28
4 Number of independent voting members of the governing body (Part VI, line 1b) .... 4 27
5 Total number of individuals employed in calendar year 2011 (Part V, line 2a) ... 5 78
6 Total number of volunteers (estimate if necessary) .... 6 17
7a Total unrelated business revenue from Part VIII, column (C), line 12 .. 7a 22,042
b Net unrelated business taxable income from Form 990-T, line 34 .. 7b 2,119
Revenues; Prior Year Current Year
8 Contributions and grants (Part VIII, line 1h) ......... 57,111,106 64,970,818
9 Program service revenue (Part VIII, line 2g) ......... 0 0
10 Investment income (Part VIII, column (A), lines 3, 4, and 7d ) .... 476,177 174,041
11 Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e) 34,177 38,514
12 Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)................... 57,621,460 65,183,373
Expenses; 13 Grants and similar amounts paid (Part IX, column (A), lines 1–3 )... 49,441,851 53,857,613
14 Benefits paid to or for members (Part IX, column (A), line 4)..... 0 0
15 Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10) 6,107,055 6,906,870
16a Professional fundraising fees (Part IX, column (A), line 11e)..... 49,600 60,000
b Total fundraising expenses (Part IX, column (D), line 25) MediumBullet4,305,375    
17 Other expenses (Part IX, column (A), lines 11a–11d, 11f–24f).... 4,458,038 4,814,498
18 Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25) 60,056,544 65,638,981
19 Revenue less expenses. Subtract line 18 from line 12....... -2,435,084 -455,608
Net Assets or Fund Balances; Beginning of Current Year End of Year
20 Total assets (Part X, line 16)............. 78,224,899 95,542,240
21 Total liabilities (Part X, line 26)............. 56,636,725 74,420,395
22 Net assets or fund balances. Subtract line 21 from line 20..... 21,588,174 21,121,845
Part II
Signature Block
Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.
Sign Here
JumboBullet
Signature of officer Date
JumboBullet
Type or print name and title.
Paid preparer use only
Print/type preparer's name
 
Preparer's signature
Date
PTIN
Firm's name Right pointing arrowhead image

Firm's EIN Right pointing arrowhead image
Firm's address Right pointing arrowhead image



Phone no.
May the IRS discuss this return with the preparer shown above? See instructions .........bullet
For Paperwork Reduction Act Notice, see the separate instructions.
Cat. No. 11282Y
Form 990 (2011)
Form 990 (2011)
Page 2
Part III
Statement of Program Service Accomplishments
Check if Schedule O contains a response to any question in this Part III .........
1
Briefly describe the organization’s mission: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA.
2
Did the organization undertake any significant program services during the year which were not listed on
the prior Form 990 or 990-EZ? ....................
If “Yes,” describe these new services on Schedule O.
3
Did the organization cease conducting, or make significant changes in how it conducts, any program services? ..........................
If “Yes,” describe these changes on Schedule O.
4
Describe the organization’s program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations and section 4947(a)(1) trusts are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.
4a (Code:   ) (Expenses $ 59,753,896 including grants of $ 53,857,613 ) (Revenue $   )
TO FUND RESEARCH FOCUSED ON DEVELOPING A CURE FOR PARKINSON'S DISEASE.
4b (Code:   ) (Expenses $   including grants of $   ) (Revenue $   )
4c (Code:   ) (Expenses $   including grants of $   ) (Revenue $   )
4d Other program services (Describe in Schedule O.)
(Expenses $   including grants of $   ) (Revenue $   )
4e Total program service expensesMediumBullet$ 59,753,896
Form 990 (2011)
Form 990 (2011)
Page 3
Part IV
Checklist of Required Schedules
Yes
No
1
Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)? If “Yes,” complete Schedule AClick to see attachment.....................
1
Yes
 
2
Is the organization required to complete Schedule B, Schedule of Contributors? Click to see attachment........
2
Yes
 
3
Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office? If “Yes,” complete Schedule C, Part I..........
3
 
No
4
Section 501(c)(3) organizations. Did the organization engage in lobbying activities? If “Yes,” complete Schedule C,
Part II.........................
4
 
No
5
Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Revenue Procedure 98-19? If “Yes,” complete Schedule C, Part III........................
5
 
 
6
Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts? If “Yes,” complete Schedule D, Part IClick to see attachment....................
6
 
No
7
Did the organization receive or hold a conservation easement, including easements to preserve open space,
the environment, historic land areas or historic structures? If “Yes,” complete Schedule D, Part IIClick to see attachment...
7
 
No
8
Did the organization maintain collections of works of art, historical treasures, or other similar assets? If “Yes,” complete Schedule D, Part III Click to see attachment....................
8
 
No
9
Did the organization report an amount in Part X, line 21; serve as a custodian for amounts not listed in Part X; or provide credit counseling, debt management, credit repair, or debt negotiation services? If “Yes,”
complete Schedule D, Part IVClick to see attachment...................
9
 
No
10
Did the organization, directly or through a related organization, hold assets in temporarily restricted endowments, permanent endowments, or quasi-endowments? If “Yes,” complete Schedule D, Part VClick to see attachment
10
 
No
11
If the organization’s answer to any of the following questions is ‘Yes,’ then complete Schedule D, Parts VI, VII, VIII, IX, or X as applicable:
a
Did the organization report an amount for land, buildings, and equipment in Part X, line10? If “Yes,” complete Schedule D, Part VI.Click to see attachment
11a
Yes
 
b
Did the organization report an amount for investments—other securities in Part X, line 12 that is 5% or more of its total assets reported in Part X, line 16? If “Yes,” complete Schedule D, Part VII.Click to see attachment
11b
 
No
c
Did the organization report an amount for investments—program related in Part X, line 13 that is 5% or more of its total assets reported in Part X, line 16? If “Yes,” complete Schedule D, Part VIII.Click to see attachment
11c
 
No
d
Did the organization report an amount for other assets in Part X, line 15 that is 5% or more of its total assets reported in Part X, line 16? If “Yes,” complete Schedule D, Part IX.Click to see attachment
11d
 
No
e
Did the organization report an amount for other liabilities in Part X, line 25? If “Yes,” complete Schedule D, Part X.Click to see attachment
11e
Yes
 
f
Did the organization’s separate or consolidated financial statements for the tax year include a footnote that addresses the organization’s liability for uncertain tax positions under FIN 48 (ASC 740)? If “Yes,” complete Schedule D, Part X.Click to see attachment
11f
Yes
 
12a
Did the organization obtain separate, independent audited financial statements for the tax year?
If “Yes,” complete Schedule D, Parts XI, XII, and XIII Click to see attachment
12a
 
No
b
Was the organization included in consolidated, independent audited financial statements for the tax year? If “Yes,” and if the organization answered ‘No’ to line 12a, then completing Schedule D, Parts XI, XII, and XIII is optional Click to see attachment
12b
Yes
 
13
Is the organization a school described in section 170(b)(1)(A)(ii)? If “Yes,” complete Schedule E
13
 
No
14a
Did the organization maintain an office, employees, or agents outside of the United States?....
14a
Yes
 
b
Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States or aggregate foreign investments valued at $100,000 or more? If “Yes,” complete Schedule F, Part I......... Click to see attachment
14b
Yes
 
15
Did the organization report on Part IX, column (A), line 3, more than $5,000 of grants or assistance to any organization or entity located outside the U.S.? If “Yes,” complete Schedule F, Part II.. Click to see attachment
15
Yes
 
16
Did the organization report on Part IX, column (A), line 3, more than $5,000 of aggregate grants or assistance to individuals located outside the U.S.? If “Yes,” complete Schedule F, Part III.. Click to see attachment
16
Yes
 
17
Did the organization report a total of more than $15,000, of expenses for professional fundraising services on Part IX, column (A), lines 6 and 11e? If “Yes,” complete Schedule G, Part IClick to see attachment
17
Yes
 
18
Did the organization report more than $15,000 total of fundraising event gross income and contributions on Part VIII, lines 1c and 8a? If “Yes,” complete Schedule G, Part II.......... Click to see attachment
18
Yes
 
19
Did the organization report more than $15,000 of gross income from gaming activities on Part VIII, line 9a? If “Yes,” complete Schedule G, Part III................... Click to see attachment
19
 
No
20a
Did the organization operate one or more hospitals? If “Yes,” complete Schedule H.....
20a
 
No
b
If “Yes” to line 20a, did the organization attach a copy of its audited financial statement to this return? Note. All Form 990 filers that operated one or more hospitals must attach audited financial statements.
20b
 
 
Form 990 (2011)
Form 990 (2011)
Page 4
Part IV
Checklist of Required Schedules (continued)
21
Did the organization report more than $5,000 of grants and other assistance to any government or organization in the United States on Part IX, column (A), line 1? If “Yes,” complete Schedule I, Parts I and II.. Click to see attachment
21
Yes
 
22
Did the organization report more than $5,000 of grants and other assistance to individuals in the United States on Part IX, column (A), line 2? If “Yes,” complete Schedule I, Parts I and III..... Click to see attachment
22
 
No
23
Did the organization answer “Yes” to Part VII, Section A, questions 3, 4, or 5, about compensation of the organization’s current and former officers, directors, trustees, key employees, and highest compensated employees? If “Yes,” complete Schedule J................ Click to see attachment
23
Yes
 
24a
Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002? If “Yes,” answer questions 24b–24d and complete Schedule K. If “No,” go to line 25................
24a
 
No
b
Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?...
24b
 
 
c
Did the organization maintain an escrow account other than a refunding escrow at any time during the year
to defease any tax-exempt bonds?......................
24c
 
 
d
Did the organization act as an “on behalf of” issuer for bonds outstanding at any time during the year?...
24d
 
 
25a
Section 501(c)(3) and 501(c)(4) organizations. Did the organization engage in an excess benefit transaction with a disqualified person during the year? If “Yes,” complete Schedule L, Part I...... Click to see attachment
25a
 
No
b
Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization’s prior Forms 990 or 990-EZ? If “Yes,” complete Schedule L, Part I................ Click to see attachment
25b
 
No
26
Was a loan to or by a current or former officer, director, trustee, key employee, highly compensated employee, or disqualified person outstanding as of the end of the organization’s tax year? If “Yes,” complete Schedule L,
Part II......................... Click to see attachment
26
 
No
27
Did the organization provide a grant or other assistance to an officer, director, trustee, key employee, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled entity or family member of any of these persons? If “Yes,” complete Schedule L, Part III......... Click to see attachment
27
 
No
28
Was the organization a party to a business transaction with one of the following parties? (see Schedule L, Part IV instructions for applicable filing thresholds, conditions, and exceptions):
a
A current or former officer, director, trustee, or key employee? If “Yes,” complete Schedule L, Part IV ......................... Click to see attachment
28a
 
No
b
A family member of a current or former officer, director, trustee, or key employee? If “Yes,”
complete Schedule L, Part IV................... Click to see attachment
28b
 
No
c
An entity of which a current or former officer, director, trustee, or key employee (or a family member thereof) was an officer, director, trustee, or owner? If “Yes,” complete Schedule L, Part IV.. Click to see attachment
28c
Yes
 
29
Did the organization receive more than $25,000 in non-cash contributions? If “Yes,” complete Schedule MClick to see attachment
29
Yes
 
30
Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? If “Yes,” complete Schedule M............ Click to see attachment
30
 
No
31
Did the organization liquidate, terminate, or dissolve and cease operations? If “Yes,” complete Schedule N,
Part I...........................
31
 
No
32
Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? If “Yes,” complete Schedule N, Part II.......................
32
 
No
33
Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? If “Yes,” complete Schedule R, Part I........ Click to see attachment
33
 
No
34
Was the organization related to any tax-exempt or taxable entity? If “Yes,” complete Schedule R, Parts II, III, IV, and V, line 1..................... Click to see attachment
34
Yes
 
35a
Did the organization have a controlled entity within the meaning of section 512(b)(13)?
35a
 
No
b
If ‘Yes’ to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)? If “Yes,” complete Schedule R, Part V, line 2... Click to see attachment
35b
 
No
36
Section 501(c)(3) organizations. Did the organization make any transfers to an exempt non-charitable related organization? If “Yes,” complete Schedule R, Part V, line 2........... Click to see attachment
36
 
No
37
Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? If “Yes,” complete Schedule R, Part VIClick to see attachment
37
 
No
38
Did the organization complete Schedule O and provide explanations in Schedule O for Part VI, lines 11 and 19? Note. All Form 990 filers are required to complete Schedule O. ............
38
Yes
 
Form 990 (2011)
Form 990 (2011)
Page 5
Part V
Statements Regarding Other IRS Filings and Tax Compliance
Check if Schedule O contains a response to any question in this Part V .........
Yes
No
1a
Enter the number reported in Box 3 of Form 1096. Enter -0- if not applicable. .......
1a
125
b
Enter the number of Forms W-2G included in line 1a. Enter -0- if not applicable.
1b
0
c
Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners? ..................
1c
Yes
 
2a
Enter the number of employees reported on Form W-3, Transmittal of Wage and Tax Statements filed for the calendar year ending with or within the year covered by this return .....................
2a
78
b
If at least one is reported on line 2a, did the organization file all required federal employment tax returns?

Note. If the sum of lines 1a and 2a is greater than 250, you may be required to e-file. (see instructions)
2b
Yes
 
3a
Did the organization have unrelated business gross income of $1,000 or more during the year?.............................
3a
Yes
 
b
If “Yes,” has it filed a Form 990-T for this year? If “No,” provide an explanation in Schedule O.....
3b
Yes
 
4a
At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account or securities account)?.......................
4a
Yes
 
b
If "Yes," enter the name of the foreign country: MediumBulletCA
See instructions for filing requirements for Form TD F 90-22.1, Report of Foreign Bank and Financial Accounts.
5a
Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?..
5a
 
No
b
Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?
5b
 
No
c
If “Yes” to line 5a or 5b, did the organization file Form 8886-T? ........
5c
 
 
6a
Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible?..........
6a
 
No
b
If “Yes,” did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?........................
6b
 
 
7
Organizations that may receive deductible contributions under section 170(c).
a
Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?....................
7a
Yes
 
b
If “Yes,” did the organization notify the donor of the value of the goods or services provided?.....
7b
Yes
 
c
Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?...........................
7c
 
No
d
If “Yes,” indicate the number of Forms 8282 filed during the year ....
7d
 
e
Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?..........................
7e
 
No
f
Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?..
7f
 
No
g
If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?...................
7g
 
 
h
If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?...............
7h
 
 
8
Sponsoring organizations maintaining donor advised funds and section 509(a)(3) supporting organizations. Did the supporting organization, or a donor advised fund maintained by a sponsoring organization, have excess business holdings at any time during the year?................
8
 
 
9
Sponsoring organizations maintaining donor advised funds.
a
Did the organization make any taxable distributions under section 4966?.........
9a
 
 
b
Did the organization make a distribution to a donor, donor advisor, or related person?......
9b
 
 
10
Section 501(c)(7) organizations. Enter:
a
Initiation fees and capital contributions included on Part VIII, line 12 ...
10a
 
b
Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities
10b
 
11
Section 501(c)(12) organizations. Enter:
a
Gross income from members or shareholders .........
11a
 
b
Gross income from other sources (Do not net amounts due or paid to other sources against amounts due or received from them) ........
11b
 
12a
Section 4947(a)(1) non-exempt charitable trusts. Is the organization filing Form 990 in lieu of Form 1041?
12a
 
 
b
If “Yes,” enter the amount of tax-exempt interest received or accrued during the year.
12b
 
13
Section 501(c)(29) qualified nonprofit health insurance issuers.
a
Is the organization licensed to issue qualified health plans in more than one state?
Note. All 501(c)(29) organizations must list in Schedule O each state in which they are licensed to issue qualified health plans, the amount of reserves required by each state, and the amount of reserves the organization allocated to each state.
13a
 
 
b
Enter the aggregate amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans.
13b
 
c
Enter the aggregate amount of reserves on hand.
13c
 
14a
Did the organization receive any payments for indoor tanning services during the tax year?.....
14a
 
 
b
If "Yes," has it filed a Form 720 to report these payments? If “No,” provide an explanation in Schedule O..
14b
 
 
Form 990 (2011)
Form 990 (2011)
Page 6
Part VI
Governance, Management, and Disclosure For each “Yes” response to lines 2 through 7b below, and for a “No” response to lines 8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions.
Check if Schedule O contains a response to any question in this Part VI .........
Section A. Governing Body and Management
Yes
No
1a
Enter the number of voting members of the governing body at the end of the tax year
If the governing body delegated broad authority to an executive committee or similar committee, explain in Schedule O.
1a
28
b
Enter the number of voting members included in line 1a, above, who are independent .................
1b
27
2
Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee? .................
2
Yes
 
3
Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person? .
3
 
No
4
Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?
4
 
No
5
Did the organization become aware during the year of a significant diversion of the organization’s assets? .
5
 
No
6
Did the organization have members or stockholders? ................
6
 
No
7a
Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body? .................
7a
 
No
b
Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body? ............
7b
 
No
8
Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:
a
The governing body? .........................
8a
Yes
 
b
Each committee with authority to act on behalf of the governing body? ..........
8b
Yes
 
9
Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization’s mailing address? If “Yes,” provide the names and addresses in Schedule O .....
9
 
No
Section B. Policies (This Section B requests information about policies not required by the Internal
Revenue Code.)
Yes
No
10a
Did the organization have local chapters, branches, or affiliates? ............
10a
 
No
b
If “Yes,” did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes? ....
10b
 
 
11a
Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?
11a
Yes
 
b
Describe in Schedule O the process, if any, used by the organization to review the Form 990. .....
12a
Did the organization have a written conflict of interest policy? If “No,” go to line 13.......
12a
Yes
 
b
Were officers, directors or trustees, and key employees required to disclose annually interests that could give rise to conflicts? ........................
12b
Yes
 
c
Did the organization regularly and consistently monitor and enforce compliance with the policy? If “Yes,” describe in Schedule O how this was done ....................
12c
Yes
 
13
Did the organization have a written whistleblower policy? ...............
13
Yes
 
14
Did the organization have a written document retention and destruction policy? .........
14
Yes
 
15
Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?
a
The organization’s CEO, Executive Director, or top management official ...........
15a
Yes
 
b
Other officers or key employees of the organization ................
15b
Yes
 
If "Yes," to line 15a or 15b, describe the process in Schedule O (see instructions).
16a
Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year? ......................
16a
 
No
b
If “Yes,” did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization’s exempt status with respect to such arrangements? ............
16b
 
 
Section C. Disclosure
17
List the States with which a copy of this Form 990 is required to be filedMediumBullet
AL , AK , AZ , AR , CA , CO , CT , FL , GA , IL , KS , KY , ME , MD , MA , MI , MN , MS , NH , NJ , NM , NY , NC , ND , OH , OK , OR , PA , RI , SC , TN , UT , VA , WA , WV , WI
18
Section 6104 requires an organization to make its Form 1023 (or 1024 if applicable), 990, and 990-T (501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
19
Describe in Schedule O whether (and if so, how), the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.
20
State the name, physical address, and telephone number of the person who possesses the books and records of the organization: MediumBullet
STEPHEN GRUBB - MJFF
GRAND CENTRAL STATION PO BOX 4777
NEW YORK,NY101634777
(212) 509-0995
Form 990 (2011)
Form 990 (2011)
Page 7
Part VII
Compensation of Officers, Directors,Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors
Check if Schedule O contains a response to any question in this Part VII .........
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
1a Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization’s tax year.
RoundBullet List all of the organization’s current officers, directors, trustees (whether individuals or organizations), regardless of amount
of compensation, and current key employees. Enter -0- in columns (D), (E), and (F) if no compensation was paid.

RoundBullet List all of the organization’s current key employees, if any. See instructions for definition of "key employee."
RoundBullet List the organization’s five current highest compensated employees (other than an officer, director, trustee or key employee)
who received reportable compensation (Box 5 of Form W-2 and/or Box 7 of Form 1099-MISC) of more than $100,000 from the
organization and any related organizations.

RoundBullet List all of the organization’s former officers, key employees, or highest compensated employees who received more than $100,000
of reportable compensation from the organization and any related organizations.

RoundBullet List all of the organization’s former directors or trustees that received, in the capacity as a former director or trustee of the
organization, more than $10,000 of reportable compensation from the organization and any related organizations.

List persons in the following order: individual trustees or directors; institutional trustees; officers; key employees; highest
compensated employees; and former such persons.
Check this box if neither the organization nor any related organizations compensated any current or former officer, director, or trustee.
(A)
Name and Title 		(B)
Average hours per week (describe hours for related organizations in Schedule O) 		(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee) 		(D)
Reportable compensation from the organization (W- 2/1099-MISC) 		(E)
Reportable compensation from related organizations (W- 2/1099-MISC) 		(F)
Estimated amount of other compensation from the organization and related organizations
Individual Trustee or Director; Institutional Trustee; Officer; Key Employee; Highest compensated employee; Former;
(1) Michael J Fox
Founder
 2.0 X           0 0 0
(2) Robert W Shackleton
Chairman
 2.0 X   X       0 0 0
(3) George E Prescott
Vice Chariman
 2.0 X   X       0 0 0
(4) Fred G Weiss
Treasurer
 2.0 X   X       0 0 0
(5) Holly S Andersen MD
Member
 2.0 X           0 0 0
(6) Eva Andersson-Dubin MD
Member
 2.0 X           0 0 0
(7) Jon Brooks
Member
 2.0 X           0 0 0
(8) Mark Booth
Member
 2.0 X           0 0 0
(9) Barry J Cohen
Member
 2.0 X           0 0 0
(10) Donny Deutsch
Member
 2.0 X           0 0 0
(11) David Einhorn
Member
 2.0 X           0 0 0
(12) Karen Finerman
Member
 2.0 X           0 0 0
(13) Nelle Fortenberry
Member
 2.0 X           0 0 0
(14) Albert B Glickman
Member
 2.0 X           0 0 0
(15) David Golub
Member
 2.0 X           0 0 0
(16) Mark L Hart III
Member
 2.0 X           0 0 0
(17) Skip Irving
Member
 2.0 X           0 0 0
Form 990 (2011)
Form 990 (2011)
Page 8
Part VII
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees (continued)
(A)
Name and Title 		(B)
Average hours per week (describe hours for related organizations in Schedule O) 		(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee) 		(D)
Reportable compensation from the organization (W- 2/1099-MISC) 		(E)
Reportable compensation from related organizations (W- 2/1099-MISC) 		(F)
Estimated amount of other compensation from the organization and related organizations
Individual Trustee or Director; Institutional Trustee; Officer; Key Employee; Highest compensated employee; Former;
(18) Edward Kalikow
Member
 2.0 X           0 0 0
(19) Katheen Kennedy
Member
 2.0 X           0 0 0
(20) Edwin A Levy
Member
 2.0 X           0 0 0
(21) Marc S Lipschultz
Member
 2.0 X           0 0 0
(22) Douglas IOstrover
Member
 2.0 X           0 0 0
(23) Tracy Pollan
Member
 2.0 X           0 0 0
(24) Ryan Reynolds
Member
 2.0 X           0 0 0
(25) Frederick E Rowe Jr
Member
 2.0 X           0 0 0
(26) Lily Safra
Member
 2.0 X           0 0 0
(27) Curtis Schenker
Member
 2.0 X           0 0 0
(28) George Whelen
Member
 2.0 X           0 0 0
(29) Katherine H Hood
Former CEO
 40.0     X       276,684 0 7,350
(30) Todd Sherer
CEO
 40.0     X       388,891 0 24,653
(31) Joanne Martz
Chief Finan and Admin Officer
 40.0     X       279,121 0 22,236
(32) Deborah W Brooks
Co-Founder
 40.0       X     474,377 0 28,402
(33) Sohini Chowdhury
VP, Research Partnerships
 40.0       X     230,026 0 13,709
(34) Sheila Kelly
Deputy Director, Advancement
 40.0       X     167,951 0 11,847
(35) Holly Barkhymer
VP, Marketing & Communications
 40.0         X   135,104 0 14,069
(36) Brian K Fiske
Director, Research Programs
 40.0         X   176,149 0 19,901
(37) Mark A Frasier
Director, Research Programs
 40.0         X   168,750 0 5,063
(38) Alison Urkowitz
Director, Research Operations
 40.0         X   136,340 0 10,898
(39) Laxmi Wordham
Chief Digital Officer
 40.0         X   130,912 0 17,962
1b Sub-Total................MediumBullet
c Total from continuation sheets to Part VII, Section A....MediumBullet
d Total (add lines 1b and 1c)............MediumBullet 2,564,305 0 176,090
2
Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organizationMediumBullet17
Yes
No
3
Did the organization list any former officer, director or trustee, key employee, or highest compensated employee on line 1a? If “Yes,” complete Schedule J for such individual .............
3
 
No
4
For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000? If “Yes,” complete Schedule J for such individual...........................
4
Yes
 
5
Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? If “Yes,” complete Schedule J for such person .....
5
 
No
Section B. Independent Contractors
1
Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization’s tax year.
(A)
Name and business address 		(B)
Description of services 		(C)
Compensation
SCHANER AND LUBITZ LLC
6391 ARLINGTIN ROAD SUITE 200
BETHESDA,MD20814 		Legal Advice 130,000
EIGHT SQUARE ACCOUNTING
666 BROADWAY SUITE 830
NEW YORK,NY10012 		Accounting Services 140,000
2
Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization MediumBullet2
Form 990 (2011)
Form 990 (2011)
Page 9
Part VIII
Statement of Revenue
(A)
Total revenue 		(B)
Related or
exempt
function
revenue 		(C)
Unrelated
business
revenue 		(D)
Revenue
excluded from
tax under sections
512, 513, or 514
Contributions, Gifts, Grants and Other Similar Amounts 1a Federated campaigns..1a  
b Membership dues....1b  
c Fundraising events....1c 4,651,256
d Related organizations...1d 2,277,800
e Government grants (contributions)1e  
f All other contributions, gifts, grants, and
similar amounts not included above1f 		58,041,762
g Noncash contributions included in lines 1a-1f:$  
h Total. Add lines 1a-1f.......MediumBullet 64,970,818
Program Service Revenue Business Code
2a
b
c
d
e
f All other program service revenue .        
g Total. Add lines 2a–2f........MediumBullet 0
Other Revenue 3 Investment income (including dividends, interest
and other similar amounts).....MediumBullet 42,326     42,326
4 Income from investment of tax-exempt bond proceeds..MediumBullet 0      
5 Royalties............MediumBullet 0      
(i) Real (ii) Personal
6a Gross rents    
b Less: rental expenses    
c Rental income or (loss)    
d Net rental income or (loss).......MediumBullet        
(i) Securities (ii) Other
7a Gross amount from sales of assets other than inventory 1,338,698  
b Less: cost or other basis and sales expenses 1,206,983  
c Gain or (loss) 131,715  
d Net gain or (loss)..........MediumBullet 131,715     131,715
8a Gross income from fundraising events (not including
$ 4,651,256
of contributions reported on line 1c). See Part IV, line 18 ...
a 795,484
b Less: direct expenses ...b 795,484
c Net income or (loss) from fundraising events..MediumBullet 0    
9a Gross income from gaming activities.
See Part IV, line 19 ...
a  
b Less: direct expenses ...b  
c Net income or (loss) from gaming activities...MediumBullet 0      
10a Gross sales of inventory, less
returns and allowances .
a 53,016
b Less: cost of goods sold ..b 30,974
c Net income or (loss) from sales of inventory..MediumBullet 22,042   22,042  
Miscellaneous Revenue Business Code
11a MISCELLANEOUS REVENUE 900,099 16,472     16,472
b            
c            
d All other revenue ....        
e Total. Add lines 11a–11d ......MediumBullet 16,472
12 Total revenue. See Instructions....MediumBullet 65,183,373   22,042 190,513
Form 990 (2011)
Form 990 (2011)
Page 10
Part IX
Statement of Functional Expenses
Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A) but are not required to complete columns (B), (C), and (D).
Check if Schedule O contains a response to any question in this Part IX. .........
Do not include amounts reported on lines 6b,
7b, 8b, 9b, and 10b of Part VIII. 		(A)
Total expenses 		(B)
Program service expenses 		(C)
Management and general expenses 		(D)
Fundraising expenses
1 Grants and other assistance to governments and organizations in the United States. See Part IV, line 21 36,887,394 36,887,394
2 Grants and other assistance to individuals in the United States. See Part IV, line 22 0 0
3 Grants and other assistance to governments, organizations, and individuals outside the United States. See Part IV, lines 15 and 16 16,970,219 16,970,219
4 Benefits paid to or for members 0  
5 Compensation of current officers, directors, trustees, and key employees .... 1,925,247 958,546 299,531 667,170
6 Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) .... 0      
7 Other salaries and wages 3,871,227 1,927,415 602,288 1,341,524
8 Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) .... 158,318 72,655 28,785 56,878
9 Other employee benefits ....... 579,702 266,035 105,399 208,268
10 Payroll taxes ........... 372,376 170,889 67,704 133,783
11 Fees for services (non-employees):        
a Management ...... 0      
b Legal ......... 129,174 32,490 18,129 78,555
c Accounting ........... 185,100   185,100  
d Lobbying ........... 0      
e Professional fundraising. See Part IV, line 17.. 60,000 60,000
f Investment management fees ...... 0      
g Other .......... 623,748 527,702   96,046
12 Advertising and promotion .... 116,271 53,258   63,013
13 Office expenses ....... 664,437 238,538 47,715 378,184
14 Information technology ...... 268,823 134,094 25,552 109,177
15 Royalties .. 0      
16 Occupancy ........... 573,023 294,422 87,642 190,959
17 Travel ............ 353,760 120,204 13,672 219,884
18 Payments of travel or entertainment expenses for any federal, state, or local public officials ...... 0      
19 Conferences, conventions, and meetings .... 944,626 944,626    
20 Interest ........... 50,916   50,916  
21 Payments to affiliates ....... 0      
22 Depreciation, depletion, and amortization ..... 135,640 71,188 18,230 46,222
23 Insurance .............. 60,178 48,722 3,513 7,943
24 Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24f. If line 24f amount exceeds 10% of line 25, column (A) amount, list line 24f expenses on Schedule O.)
a CREDIT CARD & BROKERAGE FEES 212,400 268 15,922 196,210
b OTHER SPECIAL EVENTS EXPENSE 187,701     187,701
c DONATION PROCESSING 92,986     92,986
d MARATHON RUNNER FEES 150,872     150,872
e
f All other expenses 64,843 35,231 9,612 20,000
25 Total functional expenses. Add lines 1 through 24f 65,638,981 59,753,896 1,579,710 4,305,375
26 Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here MediumBullet if following SOP 98-2 (ASC 958-720).        
Form 990 (2011)
Form 990 (2011)
Page 11
Part X Balance Sheet
(A)
Beginning of year 		(B)
End of year
Assets 1 Cash—non-interest-bearing .......... 1,724 1 104
2 Savings and temporary cash investments ....... 47,584,331 2 80,371,171
3 Pledges and grants receivable, net ......... 28,467,039 3 12,027,926
4 Accounts receivable, net ......... 0 4 0
5 Receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of
Schedule L .......... 0 5 0
6 Receivables from other disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B). Complete Part II of
Schedule L .......... 0 6 0
7 Notes and loans receivable, net ............. 0 7 0
8 Inventories for sale or use .............. 22,872 8 17,847
9 Prepaid expenses and deferred charges ............ 310,926 9 303,256
10a Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D 10a 1,673,002
b Less: accumulated depreciation. ..... 10b 1,019,579 337,060 10c 653,423
11 Investments—publicly traded securities .......... 1,467,886 11 1,339,815
12 Investments—other securities. See Part IV, line 11 ...... 0 12 0
13 Investments—program-related. See Part IV, line 11 .. 0 13 0
14 Intangible assets ......... 0 14 0
15 Other assets. See Part IV, line 11 ........... 33,061 15 828,698
16 Total assets. Add lines 1 through 15 (must equal line 34)... 78,224,899 16 95,542,240
Liabilities 17 Accounts payable and accrued expenses . 1,542,594 17 1,590,225
18 Grants payable .......... 53,453,069 18 56,245,521
19 Deferred revenue .......... 0 19 14,898,701
20 Tax-exempt bond liabilities .......... 0 20 0
21 Escrow or custodial account liability. Complete Part IV of Schedule D.. 0 21 0
22 Payables to current and former officers, directors, trustees, key
employees, highest compensated employees, and disqualified
persons. Complete Part II of Schedule L.......... 0 22 0
23 Secured mortgages and notes payable to unrelated third parties .. 0 23 0
24 Unsecured notes and loans payable to unrelated third parties .... 1,000,196 24 1,000,196
25 Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D..... 640,866 25 685,752
26 Total liabilities. Add lines 17 through 25..... 56,636,725 26 74,420,395
Net Assets or Fund Balance Organizations that follow SFAS 117, check here MediumBullet and complete lines 27 through 29, and lines 33 and 34.
27 Unrestricted net assets ..... 4,179,853 27 5,774,290
28 Temporarily restricted net assets ..... 17,408,321 28 15,347,555
29 Permanently restricted net assets ..... 0 29 0
Organizations that do not follow SFAS 117, check here MediumBullet and complete lines 30 through 34.
30 Capital stock or trust principal, or current funds .....   30  
31 Paid-in or capital surplus, or land, building or equipment fund .....   31  
32 Retained earnings, endowment, accumulated income, or other funds   32  
33 Total net assets or fund balances ..... 21,588,174 33 21,121,845
34 Total liabilities and net assets/fund balances ..... 78,224,899 34 95,542,240
Form 990 (2011)
Form 990 (2011)
Page 12
Part XI
Reconcilliation of Net Assets
Check if Schedule O contains a response to any question in this Part XI .........
1
Total revenue (must equal Part VIII, column (A), line 12) ...
1
65,183,373
2
Total expenses (must equal Part IX, column (A), line 25) ....
2
65,638,981
3
Revenue less expenses. Subtract line 2 from line 1 ...
3
-455,608
4
Net assets or fund balances at beginning of year (must equal Part X, line 33, column (A)) ..
4
21,588,174
5
Other changes in net assets or fund balances (explain in Schedule O) ...
5
-10,721
6
Net assets or fund balances at end of year. Combine lines 3, 4, and 5 (must equal Part X, line 33, column (B)) ....
6
21,121,845
Part XII
Financial Statements and Reporting
Check if Schedule O contains a response to any question in this Part XII .........
Yes
No
1
Accounting method used to prepare the Form 990:  
If the organization changed its method of accounting from a prior year or checked "Other," explain in
Schedule O.
2a
Were the organization’s financial statements compiled or reviewed by an independent accountant?....
2a
 
No
b
Were the organization’s financial statements audited by an independent accountant?........
2b
Yes
 
c
If “Yes,” to 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant? If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O. ...........................
2c
Yes
 
d
If “Yes” to line 2a or 2b, check a box below to indicate whether the financial statements for the year were issued on a separate basis, consolidated basis, or both:
3a
As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133? ................
3a
 
No
b
If “Yes,” did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits. ..
3b
 
 
Form 990 (2011)
Additional Data


Software ID:  
Software Version:  
Form 990, Special Condition Description:
Special Condition Description
SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service
Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section
4947(a)(1) nonexempt charitable trust.
right arrow Attach to Form 990 or Form 990-EZ. right arrow See separate instructions.
OMB No. 1545-0047
2011
Open to Public
Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Part I
Reason for Public Charity Status (All organizations must complete this part.) See instructions
The organization is not a private foundation because it is: (For lines 1 through 11, check only one box.)
1
2
3
4
5
section 170(b)(1)(A)(iv). (Complete Part II.)
6
7
8
9
receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of
its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses
acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)
10
11
e
f
g
(i) a person who directly or indirectly controls, either alone or together with persons described in (ii)
Yes
No
and (iii) below, the governing body of the the supported organization? ................
11g(i)
 
 
(ii) a family member of a person described in (i) above? ......................
11g(ii)
 
 
(iii) a 35% controlled entity of a person described in (i) or (ii) above? ................
11g(iii)
 
 
h
(i)
Name of supported organization 		(ii)
EIN 		(iii)
Type of organization (described on lines 1- 9 above or IRC section (see instructions)) 		(iv)
Is the organization in col. (i) listed in your governing document? 		(v)
Did you notify the organization in col. (i) of your support? 		(vi)
Is the organization in col. (i) organized in the U.S.? 		(vii)
Amount of support?
Yes No Yes No Yes No
Total                  

For Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 11285F
Schedule A (Form 990 or 990-EZ) 2011
Schedule A (Form 990 or 990-EZ) 2011
Page 2
Part II
Support Schedule for Organizations Described in IRC 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)
Section A. Public Support
Calendar year(or fiscal year beginning in) (a) 2007 (b) 2008 (c) 2009 (d) 2010 (e) 2011 (f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... 37,700,456 42,077,867 51,259,577 57,125,384 64,970,818 253,134,102
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.......            
3 The value of services or facilities furnished by a governmental unit to the organization without charge..            
4 Total. Add lines 1 through 3.. 37,700,456 42,077,867 51,259,577 57,125,384 64,970,818 253,134,102
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)..           102,332,670
6 Public Support. Subtract line 5 from line 4.           150,801,432
Section B. Total Support
Calendar year(or fiscal year beginning in) (a) 2007 (b) 2008 (c) 2009 (d) 2010 (e) 2011 (f) Total
7 Amounts from line 4.. 37,700,456 42,077,867 51,259,577 57,125,384 64,970,818 253,134,102
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. 764,390 744,930 157,415 232,554 42,326 1,941,615
9 Net income from unrelated business activities, whether or not the business is regularly carried on..            
10 Other income. (Explain in Part IV.) Do not include gain or loss from the sale of capital assets.. 117 25,682 15,213 34,177 38,514 113,703
11 Total support (Add lines 7 through 10).           255,189,420
12
12
 
13
Section C. Computation of Public Support Percentage
14
14
59.094 %
15
15
64.806 %
16a
b
17a
b
18
Schedule A (Form 990 or 990-EZ) 2011
Schedule A (Form 990 or 990-EZ) 2011
Page 3
Part III
Support Schedule for Organizations Described in IRC 509(a)(2)
(Complete only if you checked the box on line 9 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)
Section A. Public Support
Calendar year(or fiscal year beginning in) (a) 2007 (b) 2008 (c) 2009 (d) 2010 (e) 2011 (f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .            
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose......            
3 Gross receipts from activities that are not an unrelated trade or business under section 513..            
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...            
5 The value of services or facilities furnished by a governmental unit to the organization without charge..            
6 Total. Add lines 1 through 5.            
7a Amounts included on lines 1, 2, and 3 received from disqualified persons...            
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.            
c Add lines 7a and 7b..            
8 Public Support (Subtract line 7c from line 6.)            
Section B. Total Support
Calendar year (or fiscal year beginning in) (a) 2007 (b) 2008 (c) 2009 (d) 2010 (e) 2011 (f) Total
9 Amounts from line 6...            
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..            
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.            
c Add lines 10a and 10b.            
11 Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.            
12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.)            
13 Total support (Add lines 9, 10c, 11 and 12.).            
14
Section C. Computation of Public Support Percentage
15
15
 
16
16
 
Section D. Computation of Investment Income Percentage
17
17
 
18
18
 
19a
b
20
Schedule A (Form 990 or 990-EZ) 2011
Schedule A (Form 990 or 990-EZ) 2011
Page 4
Part IV
Supplemental Information. Supplemental Information. Complete this part to provide the explanation required by Part II, line 10; Part II, line 17a or 17b; or Part III, line 12. Also complete this part for any additional information. (See instructions).
Facts And Circumstances Test
 
Explanation
 
 
 
 
Schedule A (Form 990 or 990-EZ) 2011

Additional Data


Software ID:  
Software Version:  
Schedule B
(Form 990, 990-EZ,
or 990-PF)
Department of the Treasury
Internal Revenue Service
Schedule of Contributors
Arrow Bullet Attach to Form 990, 990-EZ, or 990-PF.
OMB No. 1545-0047
2011
Name of organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Organization type (check one):
Filers of:
Section:
Form 990 or 990-EZ





Form 990-PF




Check if your organization is covered by the General Rule or a Special Rule.  
Note. Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.
General Rule
Special Rules
......................... Arrow Bullet   $    
Caution. An Organization that is not covered by the General Rule and/or the Special Rules does not file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its
Form 990-EZ or on Part I, line 2, of its Form 990-PF, to certify that it does not meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).
For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.
Cat. No. 30613XSchedule B (Form 990, 990-EZ, or 990-PF) (2011)

Page 2
Schedule B (Form 990, 990-EZ, or 990-PF) (2011)
Name of organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH 		Employer identification number

13-4141945
Part I
Contributors (see Instructions). Use duplicate copies of Part I if additional space is needed.
     
(a)
No.		 (b)
Name, address, and ZIP + 4		 (c)
Total contributions		 (d)
Type of contribution
RESTRICTED
RESTRICTED
 

     
RESTRICTED
RESTRICTED  
RESTRICTED, RESTRICTED   RESTRICTED

$RESTRICTED




(Complete Part II if there is a noncash contribution.)
(a)
No.		 (b)
Name, address, and ZIP + 4		 (c)
Total contributions		 (d)
Type of contribution
 
 
 

     
 
   

$  




(Complete Part II if there is a noncash contribution.)
(a)
No.		 (b)
Name, address, and ZIP + 4		 (c)
Total contributions		 (d)
Type of contribution
 
 
 

     
 
   

$  




(Complete Part II if there is a noncash contribution.)
(a)
No.		 (b)
Name, address, and ZIP + 4		 (c)
Total contributions		 (d)
Type of contribution
 
 
 

     
 
   

$  




(Complete Part II if there is a noncash contribution.)
(a)
No.		 (b)
Name, address, and ZIP + 4		 (c)
Total contributions		 (d)
Type of contribution
 
 
 

     
 
   

$  




(Complete Part II if there is a noncash contribution.)
(a)
No.		 (b)
Name, address, and ZIP + 4		 (c)
Total contributions		 (d)
Type of contribution
 
 
 

     
 
   

$  




(Complete Part II if there is a noncash contribution.)
Schedule B (Form 990, 990-EZ, or 990-PF) (2011)

Page 3
Schedule B (Form 990, 990-EZ, or 990-PF) (2011)
Name of organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH 		Employer identification number

13-4141945
Part II
Noncash Property (see Instructions). Use duplicate copies of Part II if additional space is needed.
     
(a) No.
from
Part I		 (b)
Description of noncash property given		 (c)
FMV (or estimate)
(see instructions). 		(d)
Date received
 
$    
(a) No.
from
Part I		 (b)
Description of noncash property given		 (c)
FMV (or estimate)
(see instructions). 		(d)
Date received
 
$    
(a) No.
from
Part I		 (b)
Description of noncash property given		 (c)
FMV (or estimate)
(see instructions). 		(d)
Date received
 
$    
(a) No.
from
Part I		 (b)
Description of noncash property given		 (c)
FMV (or estimate)
(see instructions). 		(d)
Date received
 
$    
(a) No.
from
Part I		 (b)
Description of noncash property given		 (c)
FMV (or estimate)
(see instructions). 		(d)
Date received
 
$    
(a) No.
from
Part I		 (b)
Description of noncash property given		 (c)
FMV (or estimate)
(see instructions). 		(d)
Date received
 
$    
Schedule B (Form 990, 990-EZ, or 990-PF) (2011)

Page 4
Schedule B (Form 990, 990-EZ, or 990-PF) (2011)
Name of organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH 		Employer identification number

13-4141945
Part III
Exclusively religious, charitable, etc., individual contributions to section 501(c)(7), (8), or (10) organizations
that total more than $1,000 for the year. Complete columns (a) through (e) and the following line entry.
For organizations completing Part III, enter the total of exclusively religious, charitable, etc.,
contributions of $1,000 or less for the year. (Enter this information once. See instructions.) Arrow Bullet $  
Use duplicate copies of Part III if additional space is needed
(a) No.
from
Part I		 (b)
Purpose of gift		 (c)
Use of gift		 (d)
Description of how gift is held
 
(e)
Transfer of gift
Transferee's name, address, and ZIP 4 Relationship of transferor to transferee
 
 
       
 
(a) No.
from
Part I		 (b)
Purpose of gift		 (c)
Use of gift		 (d)
Description of how gift is held
 
(e)
Transfer of gift
Transferee's name, address, and ZIP 4 Relationship of transferor to transferee
 
 
       
 
(a) No.
from
Part I		 (b)
Purpose of gift		 (c)
Use of gift		 (d)
Description of how gift is held
 
(e)
Transfer of gift
Transferee's name, address, and ZIP 4 Relationship of transferor to transferee
 
 
       
 
(a) No.
from
Part I		 (b)
Purpose of gift		 (c)
Use of gift		 (d)
Description of how gift is held
 
(e)
Transfer of gift
Transferee's name, address, and ZIP 4 Relationship of transferor to transferee
 
 
       
 
Schedule B (Form 990, 990-EZ, or 990-PF) (2011)

Additional Data


Software ID:  
Software Version:  
SCHEDULE D
(Form 990)
Department of the Treasury
Internal Revenue Service
Supplemental Financial Statements
SchDMd Bullet Complete if the organization answered "Yes," to Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b
SchDMd Bullet Attach to Form 990. SchDMd Bullet See separate instructions.
OMB No. 1545-0047
2011
Open to Public Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Part I
Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" to Form 990, Part IV, line 6.
(a) Donor advised funds (b) Funds and other accounts
1 Total number at end of year .......    
2 Aggregate contributions to (during year) ...    
3 Aggregate grants from (during year) ...    
4 Aggregate value at end of year .......    
5
Did the organization inform all donors and donor advisors in writing that the assets held in donor advised
funds are the organization's property, subject to the organization's exclusive legal control? ............
6
Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be
used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................
Part II
Conservation Easements. Complete if the organization answered "Yes" to Form 990, Part IV, line 7.
1
Purpose(s) of conservation easements held by the organization (check all that apply).
2
Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.
Held at the End of the Year
a Total number of conservation easements ....................... 2a  
b Total acreage restricted by conservation easements .................. 2b  
c Number of conservation easements on a certified historic structure included in (a) ..... 2c  
d Number of conservation easements included in (c) acquired after 8/17/06, and not on a historic structure listed in the National Register .................... 2d  
3
Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during
the tax year SchDMd Bullet  
4
Number of states where property subject to conservation easement is located SchDMd Bullet  
5
Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and
enforcement of the conservation easements it holds? .............................
6
Staff and volunteer hours devoted to monitoring, inspecting and enforcing conservation easements during the year SchDMd Bullet  
7
Amount of expenses incurred in monitoring, inspecting, and enforcing conservation easements during the year
SchDMd Bullet $  
8
Does each conservation easement reported on line 2(d) above satisfy the requirements of section
170(h)(4)(B)(i) and 170(h)(4)(B)(ii)? ....................................
9
In Part XIV, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.
Part III
Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" to Form 990, Part IV, line 8.
1a
If the organization elected, as permitted under SFAS 116 (ASC 958), not to report in its revenue statement and balance sheet works of
art, historical treasures, or other similar assets held for public exhibition, education or research in furtherance of public service,
provide, in Part XIV, the text of the footnote to its financial statements that describes these items.
b
If the organization elected, as permitted under SFAS 116 (ASC 958), to report in its revenue statement and balance sheet works of art,
historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service,
provide the following amounts relating to these items:
(i)
Revenues included in Form 990, Part VIII, line 1 ........................SchDMd Bullet $  
(ii)
Assets included in Form 990, Part X ..............................SchDMd Bullet $  
2
If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under SFAS 116 (ASC 958), relating to these items:
a
Revenues included in Form 990, Part VIII, line 1 ..........................SchDMd Bullet $  
b
Assets included in Form 990, Part X ...............................SchDMd Bullet $  
For Privacy Act and Paperwork Reduction Act Notice, see the Intructions for Form 990
Cat. No. 52283D
Schedule D (Form 990) 2011

Schedule D (Form 990) 2011
Page 2
Part III
Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)
3
Using the organization’s accession and other records, check any of the following that are a significant use of its collection
items (check all that apply):
a
d
b
e
 
c
4
Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIV.
5
During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?........
Part IV
Escrow and Custodial Arrangements. Complete if the organization answered "Yes" to Form 990,
Part IV, line 9, or reported an amount on Form 990, Part X, line 21.
1a
Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................
b
If "Yes," explain the arrangement in Part XIV and complete the following table:
Amount
c Beginning balance ................................. 1c  
d Additions during the year .............................. 1d  
e Distributions during the year ............................. 1e  
f Ending balance ................................... 1f  
2a
Did the organization include an amount on Form 990, Part X, line 21? .....................
b
If “Yes,” explain the arrangement in Part XIV.
Part V
Endowment Funds. Complete if the organization answered "Yes" to Form 990, Part IV, line 10.
(a)Current Year (b)Prior Year (c)Two Years Back (d)Three Years Back (e)Four Years Back
1a Beginning of year balance ....        
b Contributions ........        
c Net investment earnings, gains, and losses ...        
d Grants or scholarships .....        
e Other expenditures for facilities
and programs ........ 		       
f Administrative expenses ....        
g End of year balance ......        
2
Provide the estimated percentage of the year end balance (line 1g) held as:
a
Board designated or quasi-endowment SchDMd Bullet  
b
Permanent endowment SchDMd Bullet  
c
Temporarily restricted endowment SchDMd Bullet  
The percentages in lines 2a, 2b, and 2c should equal 100%.
3a
Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes
No
(i) unrelated organizations ........................
3a(i)
 
 
(ii) related organizations ........................
3a(ii)
 
 
b
If "Yes" to 3a(ii), are the related organizations listed as required on Schedule R? .........
3b
 
 
4
Describe in Part XIV the intended uses of the organization's endowment funds.
Part VI
Land, Buildings, and Equipment. See Form 990, Part X, line 10.
Description of property (a) Cost or other basis (investment) (b)Cost or other basis (other) (c) Accumulated depreciation (d) Book value
1a Land .................      
b Buildings ................        
c Leasehold improvements ............   304,571 125,064 179,507
d Equipment ................   948,147 712,601 235,546
e Other .................   420,284 181,914 238,370
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).).......SchDMdBullet 653,423
Schedule D (Form 990) 2011

Schedule D (Form 990) 2011
Page 3
Part VII
Investments—Other Securities. See Form 990, Part X, line 12.
(a) Description of security or category
(including name of security)		 (b)Book value (c) Method of valuation:
Cost or end-of-year market value
(1)Financial derivatives    
(2)Closely-held equity interests    
Other








Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)Small Bullet  
Part VIII
Investments—Program Related. See Form 990, Part X, line 13.
(a) Description of investment type (b) Book value (c) Method of valuation:
Cost or end-of-year market value








Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)Small Bullet  
Part IX
Other Assets. See Form 990, Part X, line 15.
(a) Description (b) Book value








Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........Small Bullet  
Part X
Other Liabilities. See Form 990, Part X, line 25.
1.(a) Description of Liability (b) Book value
Federal Income Taxes 0
DEFERRED RENT 433,507
DUE TO MJFF CANADA 93,270
INTEREST PAYABLE 158,975






Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)Small Bullet 685,752
2. Fin 48 (ASC 740) Footnote. In Part XIV, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC740).
Schedule D (Form 990) 2011

Schedule D (Form 990) 2011
Page 4
Part XI Reconciliation of Change in Net Assets from Form 990 to Financial Statements
1 Total revenue (Form 990, Part VIII, column (A), line 12) .................... 1 65,183,373
2 Total expenses (Form 990, Part IX, column (A), line 25) ..................... 2 65,638,981
3 Excess or (deficit) for the year. Subtract line 2 from line 1 ............. 3 -455,608
4 Net unrealized gains (losses) on investments .......................... 4 -10,721
5 Donated services and use of facilities ............................. 5  
6 Investment expenses ................................... 6  
7 Prior period adjustments .................................. 7  
8 Other (Describe in Part XIV.) ................................. 8  
9 Total adjustments (net). Add lines 4 through 8 ......................... 9 -10,721
10 Excess or (deficit) for the year per financial statements. Combine lines 3 and 9 ......... 10 -466,329
Part XII Reconciliation of Revenue per Audited Financial Statements With Revenue per Return
1 Total revenue, gains, and other support per audited financial statements ....... 1 67,450,452
2 Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a Net unrealized gains on investments .......... 2a -10,721
b Donated services and use of facilities ......... 2b  
c Recoveries of prior year grants ........... 2c  
d Other (Describe in Part XIV.) ............ 2d 2,277,800
e Add lines 2a through 2d ..................... 2e 2,267,079
3 Subtract line 2e from line 1..................... 3 65,183,373
4 Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a Investment expenses not included on Form 990, Part VIII, line 7b . 4a  
b Other (Describe in Part XIV.) ........... 4b  
c Add lines 4a and 4b....................... 4c  
5 Total Revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ...... 5 65,183,373
Part XIII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return
1 Total expenses and losses per audited financial statements ............. 1 67,916,781
2 Amounts included on line 1 but not on Form 990, Part IX, line 25:
a Donated services and use of facilities .......... 2a  
b Prior year adjustments .............. 2b  
c Other losses ................ 2c  
d Other (Describe in Part XIV.) ............ 2d 2,277,800
e Add lines 2a through 2d...................... 2e 2,277,800
3 Subtract line 2e from line 1..................... 3 65,638,981
4 Amounts included on Form 990, Part IX, line 25, but not on line 1:
a Investment expenses not included on Form 990, Part VIII, line 7b .. 4a  
b Other (Describe in Part XIV.) ............ 4b  
c Add lines 4a and 4b....................... 4c  
5 Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ...... 5 65,638,981
Part XIV
Supplemental Information
Complete this part to provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b;
Part V, line 4; Part X; Part XI, line 8; Part XII, lines 2d and 4b; and Part XIII, lines 2d and 4b. Also complete this part to provide any additional information.
Identifier Return Reference Explanation
Scheduel D, Page 3, Question 2: ASC 740-10-05 Footnote The Foundation is subject to the provisions of the Financial Accounting Standards Board's Accounting Standards Codification ("ASC") 740-10-05 relating to accounting and reporting for uncertainty in income taxes. For the Foundation, ASC 740-10-05 is potentially applicable to the incurrence of unrelated business income ("UBIT") attributable to certain of the Foundation's merchandise sales. Nonetheless, because of Foundation's general tax-exempt status, ASC 740-10-05 has not had, and is not expected to have, a material impact on the Foundation's financial statements.
RECONCILIATION OF REVENUE AND EXPENSES SCHEDULE D, PARTS XII/XIII, LINES 2D, PAGE 4 AMOUNTS REPRESENT REVENUES AND EXPENSES ATTRIBUTABLE TO THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH'S CANADIAN ENTITY.
Schedule D (Form 990) 2011

Additional Data


Software ID:  
Software Version:  




SCHEDULE F(Form 990)
Department of the Treasury
Internal Revenue Service
Statement of Activities Outside the United States
Right pointing arrow large image Complete if the organization answered "Yes" to Form 990,Part IV, line 14b, 15, or 16.Right pointing arrow large image Attach to Form 990. Right pointing arrow large image See separate instructions.
OMB No. 1545-0047
2011
Open to Public Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Part I
General Information on Activities Outside the United States. Complete if the organization answered
“Yes” to Form 990, Part IV, line 14b.
1
For grantmakers. Does the organization maintain records to substantiate the amount of its grants
and other assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used
to award the grants or assistance? ..............................
2
For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other
assistance outside the United States.
3
Activites per Region. (Use Part V if additional space is needed.)
(a) Region (b) Number of offices in the region (c) Number of employees or agents in region or independent contractors (d) Activities conducted in region (by type) (e.g., fundraising, program services, investments, grants to recipients located in the region) (e) If activity listed in (d) is a program service, describe specific type of
service(s) in region		 (f) Total
expenditures for region/investments
in region
East Asia and the Pacific 0 0 Grantmaking   425,719
Europe (Including Iceland and Greenland) 0 0 Grantmaking   13,895,918
Middle East and North Africa 0 0 Grantmaking   1,552,620
North America 0 0 Grantmaking   1,095,961
North America 1 1 Maintaining offices   15,280
           
           
           
           
           
           
           
           
           
           
           
           
3a Sub-total ..... 1 1 16,985,498
b Total from continuation sheets to Part I ...      
c Totals (add lines 3a and 3b) 1 1 16,985,498
For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2011
Schedule F (Form 990) 2011
Page 2
Part II
Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" to Form 990,
Part IV, line 15, for any recipient who received more than $5,000. Check this box if no one recipient received more than $5,000 ........ MediumBullet
Use Part V if additional space is needed.
1 (a) Name of organization (b) IRS code section
and EIN (if applicable)		 (c) Region (d) Purpose of
grant 		(e) Amount of
cash grant 		(f) Manner of
cash
disbursement 		(g) Amount of
of non-cash
assistance 		(h) Description
of non-cash
assistance 		(i) Method of
valuation
(book, FMV,
appraisal, other)
Europe/Iceland/Greenland First-in-humans/patients clinical trial to assess the safety/tolerability as well as the immunogenicity and clinical activity of PD01, the first alpha-synuclein-based AFFITOPE Parkinson vaccine 1,431,450        
Europe/Iceland/Greenland Xenon inhalation to reduce L-Dopa-induced dyskinesia immunogenicity and clinical activity of PD01, the first alpha-synuclein-based AFFITOPE Parkinson vaccine 125,004        
North America Proof of Concept of Treatment with Novel Hydroxypyridinone Iron Chelators in a Non- Clinical Model of Parkinson's Disease 412,582        
Middle East/North Africa Developing a biomarker for the detection of alpha-synuclein in Parkinson's Disease Clinical Model of Parkinson's Disease 119,143        
Europe/Iceland/Greenland Small molecule screening for a-synuclein binders using Surface Plasmon Resonance (SPR). Fluorescence and radiometric competition binding assays for identification of compounds selectively binding to a-synuclein 50,000        
Europe/Iceland/Greenland Small molecule screening for a-synuclein binders using Surface Plasmon Resonance (SPR). Fluorescence and radiometric competition binding assays for identification of compounds selectively binding to a-synuclein 829,120        
Europe/Iceland/Greenland LRRK2 Cohort Consortium- Biorespository Agreement using Surface Plasmon Resonance (SPR). Fluorescence and radiometric competition binding assays for identification of compounds selectively binding to a-synuclein 453,856        
Europe/Iceland/Greenland LRRK2 role on auto-antibody production by human B cells 141,717        
Europe/Iceland/Greenland The role of LRRK2 in regulating a calcium- dependent pathway involving lysosomal stores and NAADP 125,000        
Europe/Iceland/Greenland Impact of LRRK2 kinase activity on synaptic v vesicle trafficking and NAADP 150,000        
Europe/Iceland/Greenland Investigation of the pathogenic significance of the hyperpolarization-activated current (lh) in the degeneration of substantia nigra pars compacta dopaminergic neurons. 66,660        
Europe/Iceland/Greenland Lead optimization and pharmacological characterization of selective mGluR3 PAMs as novel neuroprotective agents for Parkinson's Disease pars compacta dopaminergic neurons. 299,991        
Europe/Iceland/Greenland Generation of synthetic alpha-synuclein for the PD research community neuroprotective agents for Parkinson's Disease 199,626        
Europe/Iceland/Greenland Evaluation of ATP13A2 as a Molecular Target f or Ameliorating Alpha-Synuclein-Induced Neuro degeneration in Pre-Clinical Models of PD 246,250        
Europe/Iceland/Greenland Evaluating novel small molecule inhibitors of LRRK2 to deliver PET Ligands degeneration in Pre-Clinical Models of PD 260,000        
Europe/Iceland/Greenland NeuroEPIC Parkinson's disease study-supplement LRRK2 to deliver PET Ligands 30,000        
Europe/Iceland/Greenland PPMI Clinical Trial Site - SWEDD Amendment 55,688        
Europe/Iceland/Greenland The role of serotonergic and dopaminergic mechanisms and their interaction in L-DOPA induced dyskinesias 400,049        
Europe/Iceland/Greenland Analysis of adhesion and chemotactic factor expression possibly involved in T cell brain extravasation in Parkinson's disease: a human postmortem analysis. 93,005        
Europe/Iceland/Greenland Analysis of the ENS using routine colonic biopsies as a biomarker for PD: optimizing detecti of alpha-synuclein pathology and assessment in LRRK2 patients - SUPPLEMENT 121,769        
Europe/Iceland/Greenland Identifying Markers of PD Onset and Progression in a Prospective Cohort of Patients and Asymptomatic Carriers of LRRK2 Mutations in LRRK2 patients - SUPPLEMENT 527,242        
Europe/Iceland/Greenland Caspase-8 control microglia activation and neurotoxicity in Parkinson's disease Asymptomatic Carriers of LRRK2 Mutations 189,078        
Europe/Iceland/Greenland Functional characterization of ATP13A2, a P-type transport ATPase involved in neurodegeneration 74,993        
Europe/Iceland/Greenland Generation of LRRK2 Lentiviral Vectors transport ATPase involved in neurodegeneration 90,504        
Europe/Iceland/Greenland Identification of the LRRK2 phosphatase 143,375        
Europe/Iceland/Greenland Cognitive phenotypes in Parkinson's disease: anatomical and functional correlates 98,266        
Europe/Iceland/Greenland In vivo validation of the AAV-alpha-synuclein vectors generated by UNC for distribution to MJFF supported research community - Kirik 52,330        
Europe/Iceland/Greenland Regulated GDNF gene therapy- a novel regulatory system based on protein degradation. MJFF supported research community - Kirik 74,805        
Europe/Iceland/Greenland Fractalkine-CX3Cr1 signaling in models of Parkinson disease: Quest for novel therapeutic strategies 74,972        
Europe/Iceland/Greenland Axonopathy induced by overexpression of human -synuclein in the rat nigrostriatal dopamin e system 75,020        
Europe/Iceland/Greenland 2011 Pritzker Prize - winner -synuclein in the rat nigrostriatal dopamin e system 100,000        
Europe/Iceland/Greenland TFEB and its associated microRNA-128 as targets for neuroprotection and disease intervention in Parkinson?s disease 250,000        
Europe/Iceland/Greenland LRRK2 Target Engagement Ligand for neuroprotection and disease intervention in Parkinson?s disease 297,000        
Europe/Iceland/Greenland Assessing and diagnosing anxiety in patients with Parkinson's disease - SUPPLEMENT 431,158        
Europe/Iceland/Greenland Implementation of PD GWAS meta-analysis results on the PDGene database. 11,303        
Europe/Iceland/Greenland LRRK2 GTPase validation and inhibitor discovery on the PDGene database. 182,068        
Europe/Iceland/Greenland Activation of GPR88 by a small molecular weight compound: screening for drug-like modulators of GPR88 function. 75,000        
Europe/Iceland/Greenland Preclinical Development of Encapsulated Cell Biodelivery of GDNF for Parkinson's Disease of GPR88 function. 681,941        
East Asia/Pacific Generation of VPS35 mutant mouse model - MJFF -Elan Partnership-1373 Liffey- Original PI Beales 64,500        
Europe/Iceland/Greenland PPMI Clinical Trial Site - SWEDD Amendment -Elan Partnership-1373 Liffey- Original PI Beales 59,438        
Europe/Iceland/Greenland Ghrelin concentrations in CSF and corresponding serum samples in PD patients and controls 84,063        
East Asia/Pacific PBT434, a novel neuroprotective drug for Parkinson's disease:completion of preclinical studies to enable human clinical trials. 206,110        
Europe/Iceland/Greenland Clinical Coordination of LRRK2 Cohort Consortium Parkinson's disease:completion of preclinical studies to enable human clinical trials. 73,895        
Europe/Iceland/Greenland Dopamine D1 Positive Modulators for the Treatment of Parkinson's disease 151,444        
Europe/Iceland/Greenland Assessing the therapeutic potential of iDA neuronal cells in autologous strategy 75,000        
Europe/Iceland/Greenland Pharmacological testing of Nurr1 agonists in animal models of Parkinson's Disease 540,656        
Europe/Iceland/Greenland Next Generation Parkinson's Disease Treatment through Steering Brain Stimulation (NEXT) 366,717        
Middle East/North Africa Validation of Skp1 as a new target for PD therapy through Steering Brain Stimulation (NEXT) 238,000        
Middle East/North Africa fMRI of first degree relatives of LRRK2 positive PD patients 199,000        
Middle East/North Africa Autonomic dysfunction in LRRK2 mutation carriers: Characterization of autonomic profiles of patients with PD, carriers of mutations in the LRRK2 gene and non-manifesting first degree relatives. 249,543        
Middle East/North Africa Gait and motor symptoms in healthy asymptomatic relatives of Patients with PD carriers of mutations in the LRRK2 gene the LRRK2 gene and non-manifesting first degree relatives. 496,174        
Europe/Iceland/Greenland Targeting dramatically activated astrocytic networks for managing LID: a target validation program 140,500        
Europe/Iceland/Greenland New roles for the Parkinson's disease kinase LRRK2 in cytoskeletal dynamics program 100,025        
Europe/Iceland/Greenland Investigating signaling pathway dysfunction linked to LRRK2 249,378        
Middle East/North Africa Testing novel compounds for noninvasive delivery of small interfering RNA into CNS 74,979        
Middle East/North Africa Validation of alpha-synuclein oligomers as biomarker for Parkinson?s disease 175,783        
Europe/Iceland/Greenland Characterization of LRRK1 and LRRK2 interaction partners 200,000        
Europe/Iceland/Greenland Alpha-Synuclein Assay - Competitive Binding Study partners 18,508        
Europe/Iceland/Greenland Generation of alpha-synuclein filament protein and characterization of alpha-synuclein rabbit monoclonal antibodies 73,700        
Europe/Iceland/Greenland Regulatory T cells as modulators of microglia's inflammatory response rabbit monoclonal antibodies 200,000        
North America 2011 Pritzker Prize - runner up inflammatory response 10,000        
North America Multi-tracer positron emission tomography (PET) functional imaging as a tool to assess the relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism 252,874        
Europe/Iceland/Greenland Targeting of alpha-synuclein and SNARE complex dysfunction to restore synaptic dopamine release in a model of Parkinson disease pathology. neurochemical phenotype associated with LRRK2 mutations related Parkinsonism 75,000        
Europe/Iceland/Greenland Analysis of a viral non-coding RNA as a novel therapeutic in a chronic MPTP mouse model of Parkinson's disease and its mechanism of mitochondrial protection 149,999        
Europe/Iceland/Greenland ABILITY OF A MITOCHONDRIA IMPROVER, BERBERINE, TO ATTENUATE PARKINSON'S DISEASE Parkinson's disease and its mechanism of mitochondrial protection 57,354        
Europe/Iceland/Greenland Generation of LRRK1 protein and characterization of LRRK1 mouse and rabbit monoclonal antibodies. 14,735        
Europe/Iceland/Greenland Analysis of LRRK2 antibodies of LRRK1 mouse and rabbit monoclonal antibodies. 93,531        
Europe/Iceland/Greenland Determine the structure of Roco family proteins 249,969        
Europe/Iceland/Greenland Novel Neuroprotective Cell-Penetrating Peptides 74,580        
Europe/Iceland/Greenland CDNF (Cerebral Dopamine Neurotrophic Factor) for therapy of Parkinson's disease 180,225        
Europe/Iceland/Greenland CDNF (Cerebral Dopamine Neurotrophic Factor) for therapy of Parkinson's disease 188,819        
Europe/Iceland/Greenland PPMI Clinical Trial Site - SWEDD Amendment for therapy of Parkinson's disease 59,438        
North America The Nur77/RXR transcriptional complex as a new target in L-Dopa-induced dyskinesia treatment 100,056        
East Asia/Pacific LRRK2 physiology in Parkinson's disease target in L-Dopa-induced dyskinesia treatment 74,103        
Europe/Iceland/Greenland Predicting cognitive profiles in Parkinson's disease: A multimodal approach 153,341        
Europe/Iceland/Greenland Clinical Trial to Compare Cognitive Scales disease: A multimodal approach 1,480,549        
East Asia/Pacific C-type Natriuretic Peptide (CNP): a putative biomarker of neuronal damage in Parkinsons Disease 81,006        
Europe/Iceland/Greenland Validation of lysosomal enzymes assay in CSF - One-year extension of the RRIA: CSF lysosomal hydrolases' activity as possible marker of Parkinson's disease 100,000        
North America The relationship between cognitive phenotypes of PD with visual hallucinations and 5HT2A receptors in the inferotemporal cortex. Parkinson's disease 245,509        
Europe/Iceland/Greenland PPMI Additional Insurance for DaTscan of PD with visual hallucinations and 5HT2A receptors in the inferotemporal cortex. 14,112        
Europe/Iceland/Greenland PPMI Clinical Trial Site - SWEDD Amendment 59,438        
Europe/Iceland/Greenland 2011 - Pritzker Prize - runner up 10,000        
North America Developing a Human Neural Model for Parkinson's Disease 74,941        
Europe/Iceland/Greenland Evaluation of LRRK2-derived Bioportides as Functional Protein Modulators and Potential Therapeutics 93,269        
2
Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .....MediumBullet
46
3
Enter total number of other organizations or entities ........................MediumBullet
15
Schedule F (Form 990) 2011
Schedule F (Form 990) 2011Page 3
Part III
Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 16.
Use Part V if additional space is needed.
(a) Type of grant or assistance (b) Region (c) Number of recipients (d) Amount of
cash grant 		(e) Manner of cash
disbursement 		(f) Amount of
non-cash
assistance 		(g) Description
of non-cash
assistance 		(h) Method of
valuation
(book, FMV,
appraisal, other)
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
Schedule F (Form 990) 2011
Schedule F (Form 990) 2011
Page 4
Part IV
Foreign Forms
1 Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926 (see instructions for Form 926).................
2 Did the organization have an interest in a foreign trust during the tax year? If " Yes," the organization may be required to file Form 3520 and/or Form 3520-A. (see instructions for Forms 3520 and 3520-A)..........
3 Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with respect to Certain Foreign Corporations. (see instructions for Form 5471)..............................
4 Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If "Yes," the organization may be required to file Form 8621, Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see instructions for Form 8621)
5 Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with respect to Certain Foreign Partnerships. (see instructions for Form 8865)....................................
6 Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to file Form 5713, International Boycott Report (see instructions for Form 5713)................................................
Schedule F (Form 990) 2011
Schedule F (Form 990) 2011
Page 5
Part V
Supplemental Information
Complete this part to provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information (see instructions).
Identifier ReturnReference Explanation
SCHEDULE F PROCEDURES FOR MONITORING GRANT FUNDS OUTSIDE THE UNITED STATES: THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
Schedule F (Form 990) 2011
Additional Data


Software ID:  
Software Version:  



SCHEDULE G (Form 990 or 990-EZ)
Department of the Treasury
Internal Revenue Service
Supplemental Information Regarding
Fundraising or Gaming Activities
Complete if the organization answered "Yes" to Form 990, Part IV, lines 17, 18, or 19,or if the organization entered more than $15,000 on Form 990-EZ, line 6a.right arrowAttach to Form 990 or Form 990-EZ. right arrowSee separate instructions.
OMB No. 1545-0047
2011
Open to Public Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Part I
Fundraising Activities. Complete if the organization answered "Yes" to Form 990, Part IV, line 17.
1
Indicate whether the organization raised funds through any of the following activities. Check all that apply.
a e
b f
c g
d
2a
Did the organization have a written or oral agreement with any individual (including officers, directors, trustees
or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?
b
If “Yes,” list the ten highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization. Form 990-EZ filers are not required to complete this table.
(i) Name and address of individual
or entity (fundraiser) 		(ii) Activity (iii) Did fundraiser have custody or control of contributions? (iv) Gross receipts
from activity 		(v) Amount paid to
(or retained by)
fundraiser listed in
col. (i) 		(vi) Amount paid to
(or retained by)
organization
Yes No
Event Associates Inc Fundraising Consultants   No 0 60,000 0
Total .................right arrow 0 60,000 0
3
List all states in which the organization is registered or licensed to solicit funds or has been notified it is exempt from registration or licensing.
AL, AK, AZ, AR, CA, CO, CT, FL, GA, IL, KS, KY, ME, MD, MA, MI, MN, MS, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WV, WI
For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 50083H
Schedule G (Form 990 or 990-EZ) 2011
Schedule G (Form 990 or 990-EZ) 2011
Page 2
Part II
Fundraising Events. Complete if the organization answered "Yes" to Form 990, Part IV, line 18, or reported more than $15,000 on Form 990-EZ, line 6a. List events with gross receipts greater than $5,000.
(a) Event #1

FUNNY THING
(event type) 		(b) Event #2

BREAKING PAR
(event type) 		(c) Other Events

1
(total number) 		(d) Total Events
(Add col. (a) through col. (c))
VerticalRevenue 1 Gross receipts . . . 4,326,808 654,319 465,613 5,446,740
2 Less: Charitable
contributions . . . 		3,667,648 593,631 389,977 4,651,256
3 Gross income (line 1
minus line 2) . . . 		659,160 60,688 75,636 795,484
VerticalDirectExpenses 4 Cash prizes . . .        
5 Non-cash prizes . .     29,077 29,077
6 Rent/facility costs . . 390,310 40,079 27,650 458,039
7 Food and beverages . .   17,835   17,835
8 Entertainment . . . 239,525 2,000 14,900 256,425
9 Other direct expenses . 29,324 775 4,009 34,108
10 Direct expense summary. Add lines 4 through 9 in column (d) ........... right arrow 795,484
11 Net income summary. Combine lines 3 and 10 in column (d)............ right arrow  
Part III
Gaming. Complete if the organization answered "Yes" to Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.
VerticalRevenue (a) Bingo (b) Pull tabs/Instant
bingo/progressive bingo 		(c) Other gaming (d) Total gaming (Add col. (a) through col. (c))
1 Gross revenue . . . .        
VerticalDirectExpenses 2 Cash prizes . . . .        
3 Non-cash prizes . . .        
4 Rent/facility costs . . .        
5 Other direct expenses . .        
6 Volunteer labor . . .
 
 
 
7 Direct expense summary. Add lines 2 through 5 in column (d) ........... right arrow  
8 Net gaming income summary. Combine lines 1 and 7 in column (d) .......... right arrow  
9
Enter the state(s) in which the organization operates gaming activities:
a
Is the organization licensed to operate gaming activities in each of these states? ............
b
If "No," Explain:
 
10a
Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? .....
b
If "Yes," Explain:
 
11
Does the organization operate gaming activities with nonmembers? .................
12
Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity
formed to administer charitable gaming? ..........................
Schedule G (Form 990 or 990-EZ) 2011
Schedule G (Form 990 or 990-EZ) 2011
Page 3
13
Indicate the percentage of gaming activity operated in:
a
The organization's facility ......................
13a
 
b
An outside facility ........................
13b
 
14
Provide the name and address of the person who prepares the organization's gaming/special events books and records:
Name right arrow
Address right arrow
15a
Does the organization have a contract with a third party from whom the organization receives gaming
revenue? ......................................
b
If "Yes," enter the amount of gaming revenue received by the organization right arrow $   and the
amount of gaming revenue retained by the third party right arrow $   .
c
If "Yes," enter name and address:
Name right arrow
Address right arrow
 
 
16
Gaming manager information:
Name right arrow
Gaming manager compensation right arrow $  
Description of services provided right arrow
 
17
Mandatory distributions:
a
Is the organization required under state law to make charitable distributions from the gaming proceeds to
retain the state gaming license? ............................
b
Enter the amount of distributions required under state law distributed to other exempt organizations or spent
in the organization's own exempt activities during the tax year right arrow$  
Part IV
Complete this part to provide additional information for responses to quuestion on Schedule G (see instructions.)
Identifier ReturnReference Explanation
Schedule G (Form 990 or 990-EZ) 2011
Additional Data


Software ID:  
Software Version:  
Schedule I
(Form 990)
Department of the Treasury
Internal Revenue Service
Grants and Other Assistance to Organizations,
Governments and Individuals in the United States
Complete if the organization answered "Yes," to Form 990, Part IV, line 21 or 22.
lBullet Attach to Form 990
OMB No. 1545-0047
2011
Open to Public
Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number
13-4141945
Part I
General Information on Grants and Assistance
1
Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ....................................
2
Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.
Part II
Grants and Other Assistance to Governments and Organizations in the United States. Complete if the organization answered "Yes" to
Form 990, Part IV, line 21 for any recipient that received more than $5,000. Check this box if no one recipient received more than $5,000. Use
Part IV and Schedule I-1 (Form 990) if additional space is needed ......................... lBullet
(a) Name and address of organization
or government		 (b) EIN (c) IRC Code section
if applicable		 (d) Amount of cash grant (e) Amount of non-cash
assistance		 (f) Method of valuation
(book, FMV, appraisal,
other)		 (g) Description of
non-cash assistance		 (h) Purpose of grant
or assistance
(1) Allen Institute for Brain Science551 N 34th Street
Seattle,WA98103 		91-2155317 501(c)(3) 10,000       Characterization Study -Allen Institute Scanning Slides
(2) Allen Institute for Brain Science551 N 34th Street
Seattle,WA98103 		91-2155317 501(c)(3) 20,000       Characterization Study -Allen Institute Scanning Slides - LRRK2 Disease
(3) Aperio Technologies1360 Park Center Drive
Vista,CA92081 		33-0939292 Public Sector 6,840       Aperio Technologies Slide Hosting Scanning Slides - LRRK2
(4) Aperio Technologies1360 Park Center Drive
Vista,CA92081 		33-0939292 Public Sector 15,960       Aperio Technologies Slide Hosting - LRRK2 chaperone AT3375 to reduce alpha-synuclein levels in the brain of Thy-1 alpha-synuclein mice
(5) Avid Radiopharmaceuticals Inc4435 North First St Suite 360
Livermore,PA94551 		20-1811104 Public Sector 664,531       Developing an a-synuclein imaging agent therapeutics for PD
(6) Banner Health Institute10515 West Santa Fe Drive
Sun City,AZ85351 		86-0768795 501(c)(3) 168,214       Identifying peripheral inflammatory markers for Parkinson's disease with dementia (PDD)
(7) Banner Sun Health Research Institute10516 West Santa Fe Drive
Sun City,AZ85351 		86-0768795 501(c)(3) 55,688       PPMI Clinical Trial Site - SWEDD Amendment for Parkinson's disease with dementia (PDD)
(8) Banner Sun Health Research Institute10515 W Santa Fe Drive
Sun City,AZ85351 		86-0768795 501(c)(3) 63,971       LRRK2 Antibody Testing in Postmortem Human Brain Cell Product for Treatment of Parkinson's Disease
(9) Banner Sun Health Research Institute10515 West Santa Fe Drive
Sun City,AZ85351 		86-0768795 501(c)(3) 102,304       Characterization of inflammatory mediators during early stages of Parkinson's disease
(10) Baylor College of Medicine6550 Fannin Suite 1801
Houston,TX77030 		74-1613878 501(c)(3) 59,438       PPMI Clinical Trial Site - SWEDD Amendment during early stages of Parkinson's disease
(11) Baylor College of Medicine6501 Fannin St NB 205
Houston,TX77030 		74-1613878 501(c)(3) 74,800       Alpha-synuclein May Be Responsible for the Link Between Parkinson's Disease and Melanoma
(12) Baylor College of Medicine6550 Fannin Suite 1801
Houston,TX77030 		74-1613878 501(c)(3) 333,750       PPMI Clinical Trial Site: Year Two Between Parkinson's Disease and Melanoma
(13) Beth Israel Medical CenterSuite 5J 10 Union Square East
New York,NY10003 		13-5564934 501(c)(3) 104,473       Analytic Models in Biomarker Development
(14) Beth Israel Medical Center10 Union Square East Suite 2Q
New York,NY10003 		13-5564934 501(c)(3) 4,717,696       The Parkinson's Disease, Ashkenazi Jews and LRRK2 Consortium - a longitudinal extension
(15) Biomer Technology1047 Serpentine Lane Bldg 200
Pleastown,CA94566 		48-1286101 Public Sector 6,865       Generation of LRRK2 phospho-peptides LRRK2 Consortium - a longitudinal extension
(16) Boston UniversityRobinson C-329 715 Albany St
Boston,MA02118 		04-2103545 501(c)(3) 55,688       PPMI Clinical Trial Site - SWEDD Amendment
(17) Boston University72 E Concord Street
Boston,MA02118 		04-2103545 501(c)(3) 199,605       Role of Gad1 in l-DOPA-induced dyskinesias molecule inhibitors of cytosolic Hsp90
(18) Brandeis University415 South Street MS029
Waltham,MA024549110 		04-2103552 501(c)(3) 73,177       Caspase- 1 Inhibition to reduce cleaved alpha synuclein in rodent models of Parkinson's disease
(19) Brigham & Women's Hospital65 Landsdowne Street Suite 301A
Cambridge,MA02139 		04-2312909 501(c)(3) 74,968       Unlimited discovery of non-coding, regulatory RNAs and aberrant splicing in Parkinson's
(20) California Institute of Technology1200 E California Blvd Division of
Pasadena,CA91125 		95-6006144 501(c)(3) 150,000       Mouse Strains for Specifying Nicotinic Receptor Targets in Parkinson's Disease Neuroprotecion
(21) Ceregene Inc9381 Judicial Drive Suite 130
San Diego,CA92121 		95-4838818 Public Sector 1,000,000       A Sham- Surgery Controlled Phase 2 Trial Testing AAV2-neurturin (CERE-120) in Moderately Advanced Parkinson Disease of PD
(22) Chaperone Therapeutics IncSix Davis Drive
Triangle Park,NC27709 		26-3584962 Public Sector 149,044       Development of Hsf1 effectors as Parkinson's disease therapeutics Advanced Parkinson Disease of PD-Supplement
(23) Civitas190 Everett Ave
Chelsea,MA02150 		27-1482814 Public Sector 312,665       A Novel, Validated, Dry Powder-Based Delivery of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease Patients
(24) Cleveland Clinic9500 Euclid Avenue S-31
Cleveland,OH44195 		34-0714585 501(c)(3) 59,438       PPMI Clinical Trial Site - SWEDD Amendment of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease Patients
(25) Cleveland Clinic9500 Euclid Avenue S-31
Cleveland,OH44195 		34-0714585 501(c)(3) 257,031       PPMI Clinical Trial Site
(26) Colorado State University1680 Campus Delivery
Fort Collins,CO805231680 		84-6000545 501(c)(3) 103,993       Targeting glia in PD with novel anti- inflammatorry therapeutics
(27) Columbia University701 W168th Street
New York,NY10032 		13-5598093 501(c)(3) 74,998       DIRECT REPROGRAMMING OF CELLS INTO DOPAMINE NEURONS
(28) Columbia University650 West 168th Street BB 306
New York,NY10032 		13-5598093 501(c)(3) 74,999       Assessment of AAV Transduction with Wildtype and Constitutively Active p70S6K to Induce Axon Re-Growth in Dopamine Neurons
(29) Columbia University650 W 168th St Black Building Roo
New York,NY10032 		13-5598093 501(c)(3) 75,000       Glyt1 inhibitors promote dopaminergic striatal sprouting Axon Re-Growth in Dopamine Neurons
(30) Columbia University710 W168th St 3rd floor
New York,NY10032 		13-5598093 501(c)(3) 251,538       Neuropathological tissue collection in G2019S carriers with and without PD
(31) Coriell Institute for Medical Research403 Haddon Avenue
Camden,NJ081030000 		21-0672684 501(c)(3) 16,182       LRRK2 Cohort/PPMI Shipping Validation Study carriers with and without PD
(32) Coriell Institute for Medical Research403 Haddon Avenue
Camden,NJ081030000 		21-0672684 501(c)(3) 330,916       LRRK2 Cohort Consortium: Coriell Biorepository Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Gastric Retentive Extended-Release Tablets versus a Reference Extended-Release Tablet in Parkinson's Disease Patients
(33) Coriell Institute for Medical Research403 Haddon Avenue
Camden,NJ081030000 		21-0672684 501(c)(3) 827,468       LRRK2 Cohort Consortium: Longitudinal Efforts Biorepository Agreement Therapy in 6-OHDA Non-human Primates
(34) Covance180 Rustcraft Road
Dedham,IN020260000 		22-3265977 Public Sector 10,000       Analysis of DJ-1 levels in fifteen of PPMI qualification study CSF samples
(35) Covance180 Rustcraft Road
Dedham,IN020260000 		22-3265977 Public Sector 10,700       Alpha-Synuclein Secretion Work qualification study CSF samples
(36) Covance180 Rustcraft Road
Dedham,IN020260000 		22-3265977 Public Sector 40,920       Measurement of Abeta species in Parexel Quali Qualification Study
(37) Covance180 Rustcraft Road
Dedham,IN020260000 		22-3265977 Public Sector 65,615       Analysis of biomarkers in CSF samples from PD and elderly populations
(38) Covance180 Rustcraft Road
Dedham,IN020260000 		22-3265977 Public Sector 120,000       PPMI 2011: Hemoglobin Analyses (April 2011) and elderly populations
(39) Durin Technologies Inc2 Medical Center Drive Rm 313
Stratford,NJ080840000 		27-2247948 Public Sector 367,083       Identification and validation of blood-borne autoantibody biomarkers for detection, diagnosis and staging of Parkinson's disease
(40) Emory University615 Michael Street
Atlanta,GA303223110 		58-0566256 501(c)(3) 6,250       Characterization of inflammatory mediators during early stages of Parkinson's disease and staging of Parkinson's disease
(41) Emory University615 Michael Street
Atlanta,GA303223110 		58-0566256 501(c)(3) 25,000       Estimating neuroprotective effects of nigral AAV-NRTN using selective reaction monitoring to quantitatively measure p-erk1/2 signaling strength in nigral DA neurons
(42) Emory University1841 Clifton Road Third Floor
Atlanta,GA30329 		58-0566256 501(c)(3) 59,438       PPMI Clinical Trial Site - SWEDD Amendment AAV-NRTN using selective reaction monitoring to quantitatively measure p-erk1/2 signaling strength in nigral DA neurons
(43) Emory University615 Michael Street
Atlanta,GA30324 		58-0566256 501(c)(3) 75,000       Psychological Stress as a Risk Factor for Prarkinson's Disease
(44) Emory University1599 Clifton Road 4th
Atlanta,GA30322 		58-0566256 501(c)(3) 200,000       Role of PARK18 in Parkinson's Disease Prarkinson's Disease
(45) Envoy Therapeutics555 Heritage Drive
Jupiter,FL33458 		26-2535708 Public Sector 350,000       A Novel Oral Treatment for Parkinson's Disease Based on Highly Specific Modulation of the Indirect Pathway.
(46) Epitomics863 Mitten Road Suite 103
Burlingame,CA94010 		94-3409030 Public Sector 5,029       Additional Generation of Monoclonal LRRK2 Antibody -- LRRK2 MJFF-2 (clone c41-2) Indirect Pathway.
(47) Epitomics863 Mitten Road Suite 103
Burlingame,CA94010 		94-3409030 Public Sector 15,026       Generation of Monoclonal and Polyclonal Antib Antodies against Aggregated Forms of Alpha- Synuclein
(48) Epitomics863 Mitten Road Suite 103
Burlingame,CA94010 		94-3409030 Public Sector 15,212       Batch Antibody Production for Alessi Rabbit M Monoclonal LRRK2 Antibodies Synuclein
(49) Epitomics863 Mitten Road Suite 103
Burlingame,CA94010 		94-3409030 Public Sector 15,306       Generation of Monoclonal and Polyclonal Antibodies against LRRK1
(50) Epitomics863 Mitten Road Suite 103
Burlingame,CA94010 		94-3409030 Public Sector 15,709       Monoclonal Antibody Generation against Oxidized DJ-1
(51) Epitomics863 Mitten Road Suite 103
Burlingame,CA94010 		94-3409030 Public Sector 27,858       Alpha-Synuclein Phospho-specific Polyclonal and Monoclonal Antibody Generation
(52) Epitomics863 Mitten Road Suite 103
Burlingame,CA94010 		94-3409030 Public Sector 55,496       LRRK2 Phospho-specific Polyclonal and Monoclonal Antibody Generation
(53) Epitomics863 Mitten Road Suite 103
Burlingame,CA94010 		94-3409030 Public Sector 58,686       Additional LRRK2 Antibody Services: Phase VI-VIII Monoclonal Antibody Generation
(54) ExSAR11 Deer Park Drive Suite 103
Monmouth Junction,NJ08852 		13-4000553 Public Sector 430,059       Testing of ambroxol in the Thy1-alphaSyn mouse model of Parkinson's disease disease
(55) GeneGo500 Renaissance Drive 106
St Joeseph,MI49085 		23-1569117 Public Sector 49,093       GeneGo LRRK2 Pathway Map - Laura Brovold (Gene Go/Thomson Reuters)
(56) Gradient Biomodeling LLC8040 Juniper Drive
Park City,UT84098 		26-4634309 Public Sector 200,000       Identification of Nrf2 activators using an in silico modeling platform, followed by evaluation of these compounds in an alpha-synuclein model of PD
(57) Harvard University243 Charles St
Cambridge,MA021150000 		42-1035800 501(c)(3) 40,000       Blood-Brain Barrier Modification Using Heterotopic Nasal Mucosal Grafting for Enhanced Symptomatic and Macromolecular Disease Modifying Drug Delivery in Parkinson's Disease
(58) Harvard University25 Shattuck St
Boston,MA021150000 		42-1035800 501(c)(3) 75,000       Defining PARKIN substrates through systematic quantitative proteomics Symptomatic and Macromolecular Disease Modifying Drug Delivery in Parkinson's Disease
(59) Harvard University65 Landsdowne Street Suite 301A
Cambridge,MA021390000 		42-1035800 501(c)(3) 150,000       Alpha-synuclein expression lowering therapeutics: Hit confirmation
(60) Harvard University115 Mill Street
Belmont,MA024780000 		42-1035800 501(c)(3) 225,000       Duloxetine hydrochloride as a novel neuroprotective treatment for Parkinson's disease
(61) Henry Ford Health System - Henry Ford Hospital5777 West Maple Road
West Bloomfield,MI48322 		38-1357020 501(c)(3) 506,282       Droxidopa treatment of gait, sleep, and cognitive disorders in Parkinson's disease
(62) Impax Laboratories Inc31047 Genstar Rd
Hayward,CA94544 		65-0403311 Public Sector 400,000       Testing effects of improved l-dopa delivery with dexterity and gait objective measures
(63) Indiana University410 West Tenth Street HS 4021 Indi
Indianapolis,IN462023002 		35-6001673 501(c)(3) 10,020       Storage of biospecimens from MJFF biomarker study
(64) Indiana University410 West Tenth Street HS 4021 Indi
Indianapolis,IN462023002 		35-6001673 501(c)(3) 24,309       Mega-Meta-Analysis and Neurochip Development study
(65) Indiana University410 West Tenth Street HS 4021 Indi
Indianapolis,IN462023002 		35-6001673 501(c)(3) 137,491       Storage and Distribution of DATATOP samples
(66) Invitrogen Corporation501 Charmany Drive
Madison,NY53719 		33-0373077 Public Sector 11,800       LRRK2 Biochemical Studies (Invitrogen/Nichols
(67) Invitrogen Corporation501 Charmany Drive
Madison,NY53719 		33-0373077 Public Sector 100,150       Generation of Full Length LRRK2 protein by Invitrogen
(68) Johns Hopkins University600 N Wolfe Street Meyer 6-119B
Baltimore,MD21287 		52-0595110 501(c)(3) 59,438       PPMI Clinical Trial Site - SWEDD Amendment Invitrogen
(69) Lauren Sciences LLC71 East 77th Street Suite 8A
New York,NY10075 		27-3076076 Public Sector 321,464       Delivery of GDNF to the Brain by Novel Nanovesicles for the Treatment of PD
(70) Lucigen Corporation2120 W Greenview Dr Ste 9
Middleton,WI53562 		39-1923306 Public Sector 185,416       Screening & Identification of small-molecule pharmacophores modulating LRRK2 activity
(71) Mayo Clinic4500 San Pablo Road
Jacksonville,FL32224 		59-3337028 501(c)(3) 28,097       Characterization of LRRK2 monoclonal antibodies in rodent brain tissue--Melrose
(72) Mayo Clinic13400 E Shea Blvd
Scottsdale,AZ85259 		59-3337028 501(c)(3) 50,000       Salivary Gland Biopsies as a Diagnostic Test for Parkinson's Disease Tolerability Study of Isradipine as a Disease Modifying Agent in Patients With Early Parkinson's Disease
(73) McLean Hospital115 Mill Street
Belmont,MA02478 		04-2697981 501(c)(3) 75,000       Xenon Neuroprotection in a Rat Parkinson's Model for Parkinson's Disease efficacious approach to treating Parkinson's disease
(74) McLean Hospital115 Mill Street
Belmont,MA02478 		04-2697981 501(c)(3) 125,000       Inhibition of LINGO-1 as a novel target for regeneration in preclinical PD models
(75) Melior Discovery860 Springdale Drive
Exton,PA19341 		20-2055208 Public Sector 324,750       Evaluation of a Specific DAT Inhibitor in Pre- clinical Models of Parkinson's Disease
(76) Michigan State University33 Bostwick Ave NE
Grand Rapids,MI49503 		38-6005984 501(c)(3) 74,999       Alpha-Synuclein Knockdown: Therapeutic or Toxic? clinical Models of Parkinson's Disease
(77) Molecular Neuroimaging LLC60 Temple Street 8th floor
New Haven,CT065100000 		06-0582206 Public Sector 588,506       Development of functional imaging for CB-1 and 5-HT1a in PD participants with Dyskinesia
(78) Mount Sinai School of MedicineBox 1137 One Gustave L Levy Place
New York,NY10029 		13-6171197 501(c)(3) 49,727       LRRK2 Immunocytochemistry in Cultured Neurons 5-HT1a in PD participants with Dyskinesia
(79) Mount Sinai School of MedicineBox 1137 One Gustave L Levy Place
New York,NY10029 		13-6171197 501(c)(3) 250,000       Structural, post-translational modification and small chemical approaches to understand LRRK2 function in PD treatment of L-DOPA-induced dyskinesias. - Linked to Bjorklund CIA 2009
(80) Mount Sinai School of MedicineBox 1137 One Gustave L Levy Place
New York,NY10029 		13-6171197 501(c)(3) 262,491       LRRK2 Effects on Neural Differentiation and small chemical approaches to understand LRRK2 function in PD
(81) National Institute on Aging35 Convent Drive Building 35 Room
Bethesda,MD20892 		52-2038294 501(c)(3) 50,000       Biochemical characterization of full length human recombinant LRRK1 and LRRK2
(82) National Institute on Drug Abuse (NIDA)NIH251 Bayview Blvd 06A721
Baltimore,MD21224 		52-0858115 501(c)(3) 400,000       DPP-4 inhibitors for the treatment of Parkinson's Disease
(83) NeuroHealing Pharmaceuticals Inc50 Undine Road Unit 1
Newton,MA021350000 		74-3095627 Public Sector 500,000       NH004 Films for Sialorrhea in PD Patients Parkinson's Disease
(84) Neurolixis Inc29432 Clipper Way
Laguna Niguel,CA92677 		45-2236871 Public Sector 249,355       Enhanced activity in rodent models of Parkinsonism and L-DOPA-induced dyskinesias by preferential targeting of subpopulations of 5-HT1A receptors.
(85) Neurologix IncOne Bridge Plaza Suite 695
Fort Lee,NJ070240000 		06-1582875 Public Sector 199,815       Neurologix Gene Therapy AAV-GAD Phase 3 Product Development preferential targeting of subpopulations of 5-HT1A receptors.
(86) NeuroPhage Pharmaceuticals222 Third Street Suite 3120
Cambridge,MA021420000 		20-8558071 Public Sector 147,140       Characterization of NPT001-mediated alpha- synuclein disaggregation and clearance
(87) Neuroscience Associates10915 Lake Ridge Drive
Knoxville,TN379344919 		62-1540123 Public Sector 158,028       Characterization Study -NeuroScience Associates Mouse and Rat Characterization-ELAN
(88) Neuroscience Associates10915 Lake Ridge Drive
Knoxville,TN379344919 		62-1540123 Public Sector 197,382       Characterization Study -NeuroScience Associates Mouse and Rat Characterization- LRRK2
(89) New York University145 East 32nd Street 2nd Floor
New York,NY10016 		13-5562308 501(c)(3) 507,804       Bioanatomical Phenotype of Parkinson's disease with and without cognitive impairment
(90) Northwestern University710 North Lake Shore Drive 1425 Ab
Chicago,IL60611 		36-2167817 501(c)(3) 19,233       2011 PPMI Steering Committee Grant for Tanya Simuni
(91) Northwestern University710 North Lake Shore Drive 1425 Ab
Chicago,IL60611 		36-2167817 501(c)(3) 99,063       PPMI Clinical Trial Site - SWEDD Amendment Simuni
(92) Northwestern University303 E Chicago Ave
Chicago,IL60611 		36-2167817 501(c)(3) 248,532       Identification of a novel calcium selective antagonist for neuroprotection in PD
(93) ORC International902 Carnegie Center Suite 220
Princeton,NJ085400000 		22-3118960 Public Sector 83,800       ORC Survey Project - 2011 antagonist for neuroprotection in PD
(94) Oregon Health & Science University3181 SW Sam Jackson Park Rd OP-32
Portland,OR97239 		93-1176109 501(c)(3) 25,188       PPMI 2011: TAP-PD Ancillary Study OHSU
(95) Oregon Health & Science University3181 SW Sam Jackson Park Rd OP-32
Portland,OR97239 		93-1176109 501(c)(3) 55,688       PPMI Clinical Trial Site - SWEDD Amendment PD program
(96) Oregon Health & Science University3181 SW Sam Jackson Park Road
Portland,OR97239 		93-1176109 501(c)(3) 149,900       Increased sensitivity to the loss of nigrostriatal dopamine following progressive MPTP treatment in LRRK2 mutant mice.
(97) Oregon Health & Science University3181 SW Sam Jackson Park Rd OP-32
Portland,OR97239 		93-1176109 501(c)(3) 333,750       PPMI Clinical Trial Site: Year Two nigrostriatal dopamine following progressive MPTP treatment in LRRK2 mutant mice.
(98) Parexel1560 Chevy Chase Drive Suite 140
Glendale,IL91206 		04-3517643 Public Sector 38,400       PAREXEL Protocol Development for Sanofi Trial MJFF-6/7/8/9-P3520/P3521/P3522/P3523
(99) Parexel1560 Chevy Chase Drive Suite 140
Glendale,IL91206 		04-3517643 Public Sector 672,570       Collection of blood and CSF from people with Parkinson's disease over 24-36 hours
(100) Parkinson's Action Network1025 Vermont Ave NW Suite 1120
Washington,DC20005 		94-3172675 501(c)(3) 250,000       PAN Funding 2011 Parkinson's disease over 24-36 hours
(101) Parkinson's Disease and Movement Disorder Center o951 NW 13th Street Bldg 5-E
Boca Raton,FL33486 		22-3659456 501(c)(3) 326,969       PPMI Clinical Trial Site
(102) Pfizer Global Research and DevelopmentEastern Point Road
Groton,CT063400000 		14-1396954 Public Sector 326,000       Development of LRRK2 Target Engagement Ligands
(103) Proteos4717 Campus Drive
Kalamazoo,MI49008 		26-0069252 Public Sector 65,861       PINK1 Protein Generation (Proteos) of Parkinson's disease in a rat animal model
(104) PsychoGenics765 Old Saw Mill River Road Suite 2
Tarrytown,NY10591 		13-4034631 Public Sector 350,000       SmartCube Characterization Study - Characteri- zation of DJ1 and PINK1 KO Rats
(105) Rush University1735 W Harrison Suite 324
Chicago,IL60612 		36-2174823 501(c)(3) 74,920       Intestinal microbiota, permeability and alpha- synclein aggregation in Parkinson's disease
(106) Rush University1735 West Harrison Street Suite 30
Chicago,IL60612 		36-2174823 501(c)(3) 74,997       Nmnat function in axonal neuroprotection synclein aggregation in Parkinson's disease
(107) Rush University1735 West Harrison Street Suite 30
Chicago,IL60612 		36-2174823 501(c)(3) 124,645       Gene delivery of miRNAs to reduce alpha synuclein: a new therapy for PD
(108) Saint Jude Children's Research Hospital332 North Lauderdale
Memphis,TN38105 		16-2064601 501(c)(3) 93,640       GSTpi as a Blood Based Biomarker for Parkinson's Disease
(109) SeaChange Pharmaceuticals Inc1700 4TH ST BYERS HALL STE 214
SAN FRANCISCO,CA941582330 		27-0530771 Public Sector 74,920       Identifying approved and investigational drugs with activity on Parkinson's disease targets
(110) SpringBox Ltd708 Congress Avenue Austin Texas 7
Austin,TX78701 		84-1643767 Public Sector 6,300       Fox Trial Finder Discovery and Build Out-2011 addition- Supplement
(111) SpringBox Ltd708 Congress Ave
Austin,TX78701 		84-1643767 Public Sector 28,770       Fox Trial Finder Discovery and Build Out-2011 addition
(112) Stanford University299 Campus Drive
Stanford,CA94305 		94-1156365 501(c)(3) 75,000       Transport and transfer of misfolded alpha- synuclein in neurons
(113) Stanford University3801 Miranda Avenue Bldg100 Rm D3-
Palo Alto,CA94306 		94-1156365 501(c)(3) 125,000       TGF-beta Signaling as Novel Therapeutic Treatment for Parkinson's Disease
(114) Stanford UniversityRm A343 300 Pasteur Drive
Stanford,CA94305 		94-1156365 501(c)(3) 428,629       Development of multimodal imaging biomarkers for cognitive dysfunction in Parkinson's disease
(115) State University of New York at Binghamton4400 Vestal Parkway East Science I
Binghamton,NY139026000 		14-1368361 501(c)(3) 248,750       Targeting Serotonin Transporters for the treatment of L-DOPA-induced Dyskinesia
(116) State University of New York at Buffalo124 Sherman Hall
Buffalo,NY14214 		14-1368361 501(c)(3) 150,000       Generating Patient-Specific Induced Pluripotent Stem Cells to Study Parkinson's Disease
(117) SynAgile Corporation6114 LaSalle Ave 427
Oakland,CA94611 		27-4644283 Public Sector 699,999       Continuous Subcutaneous Levodopa Prodrug Infusion
(118) Taconic5 Cedar Brook Drive
Cranbury,NJ085120000 		33-0675808 Public Sector 37,931       Characterization Study -Taconic Aging of CJ Li's LRRK2 Rats
(119) Taconic5 Cedar Brook Drive
Cranbury,NJ085120000 		33-0675808 Public Sector 59,000       Generation of GBA mutant mice LRRK2 Rats
(120) Taconic5 Cedar Brook Drive
Cranbury,NJ085120000 		33-0675808 Public Sector 71,620       Taconic TH-GFP Rat Generation a comparison of CSF and blood
(121) Targacept Inc200 East First Street Suite 300
WinstonSalem,NC271014165 		56-2020050 Public Sector 499,663       Effect of Novel Neuronal Nicotinic Receptor C Compounds on Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
(122) The Institute for Neurodegenerative Disorders60 Temple Street Suite 8B
New Haven,CT065100000 		06-1582206 501(c)(3) 10,938       PPMI 2011: Leadership Core Support for 'Three Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarkers Study (TAP-PD), A PPMI Sub-study'
(123) The Institute for Neurodegenerative Disorders60 Temple St Suite 8B
New Haven,CT065110000 		06-1582206 501(c)(3) 25,188       PPMI 2011: TAP-PD Ancillary Study IND Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarkers Study (TAP-PD), A PPMI Sub-study'
(124) The Institute for Neurodegenerative Disorders60 Temple Street Suite 8B
New Haven,CT065100000 		06-1582206 501(c)(3) 42,500       PPMI 2011: SWEDD Addendum -- Support for Leadership Core
(125) The Institute for Neurodegenerative Disorders60 Temple Street Suite 8B
New Haven,CT065100000 		06-1582206 501(c)(3) 42,604       PPMI: 2011 Support for Study Call Center Leadership Core
(126) The Institute for Neurodegenerative Disorders60 Temple Street Suite 8B
New Haven,CT065100000 		06-1582206 501(c)(3) 62,500       PPMI 2011: Leadership Core Support for Australia Expansion
(127) The Institute for Neurodegenerative Disorders60 Temple Street 8th floor
New Haven,CT065100000 		06-1582206 501(c)(3) 82,085       PPMI 2011: Datscan Validation and Regulatory Setup for PPMI Imaging at IND
(128) The Institute for Neurodegenerative Disorders60 Temple St Suite 8B
New Haven,CT065110000 		06-1582206 501(c)(3) 92,813       PPMI Clinical Trial Site - SWEDD Amendment Setup for PPMI Imaging at IND
(129) The Institute for Neurodegenerative Disorders60 Temple Street Suite 8B
New Haven,CT065100000 		06-1582206 501(c)(3) 143,750       PPMI 2011: SWEDD Sub-Study Support for Imaging Core
(130) The Institute for Neurodegenerative Disorders60 Temple Street Suite 8B
New Haven,CT065100000 		06-1582206 501(c)(3) 295,867       DAT imaging in unaffected LRRK2 gene positive subjects in a Chinese community cohort
(131) The Institute for Neurodegenerative Disorders60 Temple St Suite 8B
New Haven,CT065110000 		06-1582206 501(c)(3) 333,750       PPMI Clinical Trial Site: Year Two subjects in a Chinese community cohort blocks alpha-synuclein oligomerization
(132) The Institute for Neurodegenerative Disorders60 Temple Street Suite 8B
New Haven,CT065100000 		06-1582206 501(c)(3) 346,704       PPMI Leadership Core - Year 2 Funding
(133) The Institute for Neurodegenerative Disorders60 Temple Street Suite 8B
New Haven,CT065100000 		06-1582206 501(c)(3) 627,434       PPMI Imaging Core - Year 2 Funding disease
(134) The Jackson Laboratory610 Main Street
Bar Harbor,ME046090000 		01-0211513 501(c)(3) 21,000       LRRK gene Knockout Mice Importing, rederivation, development of allele-specific genotyping assay, crossing to homozygosity, maintaining live colonies, cross LRRK1 and LRRK2 to make double KG, cryopreservation, maintaining colonies
(135) The Jackson Laboratory610 Main Street
Bar Harbor,ME046090000 		01-0211513 501(c)(3) 23,010       LRRK2 Kinase Dead Mice DNA Preparation, BAC m microinjections, gestation, weaning, and genotyping to identify founders live colonies, cross LRRK1 and LRRK2 to make double KG, cryopreservation, maintaining colonies
(136) The Jackson Laboratory610 Main Street
Bar Harbor,ME046090000 		01-0211513 501(c)(3) 67,830       Characterization Study -JAX Breeding and Aging microinjections, gestation, weaning, and genotyping to identify founders
(137) The Jackson Laboratory610 Main Street
Bar Harbor,ME046090000 		01-0211513 501(c)(3) 81,000       shipping and housing of academic models - non LRRK2
(138) The Jackson Laboratory610 Main Street
Bar Harbor,ME046090000 		01-0211513 501(c)(3) 81,000       shipping and housing of academic models - LRRK2 LRRK2 stimulating alpha4beta2* nAChRs
(139) The Jackson Laboratory610 Main Street
Bar Harbor,ME046090000 		01-0211513 501(c)(3) 199,000       LRRK2 Knock-In mice - JAX model creation Neurosteroids: A Novel Therapeutic Strategy to Treat Parkinson's Disease
(140) The Jackson Laboratory610 Main Street
Bar Harbor,ME046090000 		01-0211513 501(c)(3) 200,000       Primary Characterization/selection of Founders of Taconic Lines-mRNA-Protein MJFF7-12
(141) The Jackson Laboratory610 Main Street
Bar Harbor,ME046090000 		01-0211513 501(c)(3) 302,620       LRRK2 BAC Transgenic mice - Regeneration of Taconic Lines-mRNA-Protein MJFF7-12
(142) The Jackson Laboratory610 Main Street Bar Harbor Maine 0
Bar Harbor,ME046090000 		01-0211513 501(c)(3) 348,344       Primary Characterization/selection of founders of Taconic Lines-LRRK2
(143) The Parkinson's Institute675 Almanor Avenue
Sunnyvale,CA94089 		94-3061594 501(c)(3) 10,000       2011 - Pritzker Prize - runner up of Taconic Lines-LRRK2
(144) The Parkinson's Institute675 Almanor Avenue
Sunnyvale,CA94085 		94-3061594 501(c)(3) 25,443       PPMI Steering Comittee 2011 - Caroline Tanner characterization
(145) The Parkinson's Institute675 Almanor Avenue
Sunnyvale,CA94085 		94-3061594 501(c)(3) 59,438       PPMI Clinical Trial Site - SWEDD Amendment
(146) The Parkinson's Institute675 Almanor Avenue
Sunnyvale,CA94085 		94-3061594 501(c)(3) 249,454       Increasing the Sensitivity of LRRK2 Assays: Development of Proximity Ligation Assays for LRRK2
(147) The Parkinson's Institute675 Almanor Avenue
Sunnyvale,CA94085 		94-3061594 501(c)(3) 251,667       Assessment of the pharmacokinetics (PK) and Cognitive Side Effects of the Antidyskinetic Drug Fenobam in MPTP-treated squirrel monkeys
(148) The Parkinson's Institute675 Almanor Avenue
Sunnyvale,CA94089 		94-3061594 501(c)(3) 266,459       Maintaining of a colony of parkinsonian non- human primates as a resource for pre-clinical drug trials
(149) Trevena Inc1018 W 8th Ave Ste A
King of Prussia,PA19406 		26-1469215 Public Sector 205,495       Pathway validation of a biased delta opioid receptor ligand for PD symptomatic relief drug trials
(150) UMDNJ-Robert Wood Johnson Medical School-(Universi683 Hoes Lane Room 180
Piscataway,CA088540000 		23-7313160 501(c)(3) 274,986       The Repositioning of Nalbuphine for the Treat Treatment of LID
(151) University of Alabama at Birmingham1719 6th Ave S CIRC 516
Birmingham,AL35294 		60-0539600 501(c)(3) 26,425       Characterization of LRRK2 monoclonal antibodies in rodent brain tissue--West
(152) University of Alabama at Birmingham1719 6th Ave South CIRC 516
Birmingham,AL352940021 		60-0539600 501(c)(3) 55,688       PPMI Clinical Trial Site - SWEDD Amendment in rodent brain tissue--West
(153) University of Alabama at Birmingham1719 6th Ave S CIRC 560D
Birmingham,AL35294 		60-0539600 501(c)(3) 125,000       14-3-3s as Regulators of LRRK2 Toxicity Detection of Parkinson's Disease
(154) University of Alabama at Birmingham1719 6th Ave South CIRC 516
Birmingham,AL352940021 		60-0539600 501(c)(3) 333,750       PPMI Clinical Trial Site: Year Two Parkinson's Disease.
(155) University of California Los Angeles635 Charles E Young Drive South
Los Angeles,CA900957334 		95-6006143 501(c)(3) 18,750       PPMI 2011 - 'Three Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), A Parkinson's Progression Markers Initiative (PPMI) Sub-study' - Support for Bioinformatics Core
(156) University of California Los Angeles635 Charles E Young Drive South S
Los Angeles,CA900957334 		95-6006143 501(c)(3) 75,000       PPMI 2011: Bioinformatics Core Support for Australia Expansion Biomarker Study (TAP-PD), A Parkinson's Progression Markers Initiative (PPMI) Sub-study' - Support for Bioinformatics Core
(157) University of California Los Angeles621 Charles E Young Dr South
Los Angeles,CA90095 		95-6006143 501(c)(3) 98,413       A New Strategy to Ameliorate Chemically-Induced Parkinson-like Symptoms by Engaging the Spinal Locomotor Circuitry with Epidural Stimulation
(158) University of California Los Angeles11301 Wilshire Blvd Bldg 115
Los Angeles,CA90073 		95-6006143 501(c)(3) 125,000       Ghrelin agonist as a novel therapeutic approach to alleviate gut dysmotility and levodopa- inhibited gastric emptying in PD models Stimulation
(159) University of California Los Angeles635 Charles E Young Drive South S
Los Angeles,CA900957334 		95-6006143 501(c)(3) 156,250       PPMI 2011: SWEDD Substudy Support for Bioinf Bionformatics Core at LONI inhibited gastric emptying in PD models
(160) University of California Los Angeles635 Charles E Young Drive South S
Los Angeles,CA900957334 		95-6006143 501(c)(3) 306,726       PPMI Bioinformatics Core - Year 2 Funding Bionformatics Core at LONI Tunisia
(161) University of California Los Angeles650 Charles Young Drive
Los Angeles,CA900951735 		95-6006143 501(c)(3) 550,000       Repositioning BCG vaccination as an Immunostimulant for Slowing the Progression of PD optimization for clinical study
(162) University of California San Diego9500 Gilman Drive 0662
La Jolla,CA920930662 		95-2544535 501(c)(3) 55,688       PPMI Clinical Trial Site - SWEDD Amendment Immunostimulant for Slowing the Progression of PD efficacy of ADX48621 in the treatment of moderate to severe L-dopa induced dyskinesia in patients with Parkinson's disease
(163) University of California San Francisco4150 Clement St 114M
San Francisco,CA94121 		94-6036493 501(c)(3) 62,500       PPMI 2011: DTI Core Support for Australia Ex Expansion
(164) University of California San Francisco505 Parnassus Ave Rm M779
San Francisco,CA94143 		94-6036493 501(c)(3) 75,000       Effect of deep brain stimulation on cortical cross frequency coupling in Parkinson's disease: an electrocorticography study
(165) University of California San Francisco4150 Clement St 114M
San Francisco,CA94121 		94-6036493 501(c)(3) 75,000       PPMI 2011: SWEDD Addendum -- Support for DTI Core an electrocorticography study Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy
(166) University of California San Francisco600 16th Street MC 2280
San Francisco,CA941582280 		94-6036493 501(c)(3) 75,000       Drug Rescue of PINK1 Kinase Activity - A New Therapeutic Modality For Treating PD
(167) University of California San Francisco4150 Clement St 114M
San Francisco,CA94121 		94-6036493 501(c)(3) 102,587       PPMI 2011: DTI Analysis Core - Year 2 Funding Therapeutic Modality For Treating PD
(168) University of California San Francisco4150 Clement St 114M
San Francisco,CA94121 		94-6036493 501(c)(3) 487,211       Multimodal MRI Markers for Parkinson's Disease compound
(169) University of Chicago5841 S Maryland Avenue MC 2030
Chicago,IL60637 		36-2177139 501(c)(3) 24,821       Development of highly sensitive and specific antibodies against oxidized DJ-1 as a biomarker for Parkinson's disease
(170) University of Chicago5841 S Maryland Avenue MC 2030
Chicago,IL60637 		36-2177139 501(c)(3) 221,948       Modulation of striatal cholinergic neuronal activity in LID for Parkinson's disease
(171) University of Florida100 S Newell Dr Room L1-100A
Gainesville,FL32610 		59-6002052 501(c)(3) 43,750       In vivo validation of the AAV-alpha-synuclein vectors generated by UNC for distribution to MJFF supported research community - Mandel Parkinson's disease
(172) University of Florida2033 Mowry Rd PO Box 103610
Gainesville,FL32610 		59-6002052 501(c)(3) 250,000       The Unfolded Protein Response (UPR) chaperone GRP78/BiP as a therapeutic target for alpha- synuclein toxicity.
(173) University of Iowa2450 University Capitol Center
Iowa City,IA52242 		42-6004813 501(c)(3) 15,625       PPMI 2011 - Statistic Core Support for 'Three Site Assesment of the Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), A PPMI Sub-study'
(174) University of Iowa2450 University Capitol Center
Iowa City,IA52242 		42-6004813 501(c)(3) 81,250       PPMI 2011: SWEDD Addendum - Support for Stat Statistics Core Monitoring in a PD Biomarker Study (TAP-PD), A PPMI Sub-study'
(175) University of Iowa2450 University Capitol Center
Iowa City,IA52242 		42-6004813 501(c)(3) 210,096       PPMI Statistics Core - Year 2 Funding Statistics Core
(176) University of Iowa2450 University Capitol Center
Iowa City,IA52242 		42-6004813 501(c)(3) 500,261       LRRK2 Cohort Consortium - Statisical Work improvement of regeneration in PD
(177) University of Minnesota321 Church St Rm 6-145 Jackson Hal
Minneapolis,MN55455 		41-6007513 501(c)(3) 75,000       Alpha-synuclein and tau mislocalization to dendritic spines Parkinson's disease and L-dopa treatment response
(178) University of North Carolina at Chapel Hill3009 Thurston CB 7178
Chapel Hill,NC275997178 		56-6001393 501(c)(3) 74,402       The Development of Novel Adeno-associated Virus Vectors for Intravenous Parkinson's Gene Therapy Later Life
(179) University of North Carolina at Chapel HillThurston Bowles Building Rm 7119
Chapel Hill,NC27599 		56-6001393 501(c)(3) 100,500       Generation of alpha-synuclein viral vectors Vectors for Intravenous Parkinson's Gene Therapy
(180) University of Pennsylvania330 South 9th Street
Philadelphia,PA19104 		23-1352685 501(c)(3) 25,188       PPMI 2011: TAP-PD Ancillary Study UPenn alpha-synuclein in the nucleus: DNA binding and transcriptional dysregulation
(181) University of Pennsylvania330 South 9th Street
Philadelphia,PA19104 		23-1352685 501(c)(3) 55,688       PPMI Clinical Trial Site - SWEDD Amendment L-DOPA-induced dyskinesia
(182) University of Pennsylvania3400 Spruce Street
Philadelphia,PA19104 		23-1352685 501(c)(3) 268,216       PPMI 2011: Bioanalytics Core - Year 2 Funding alpha-synuclein pathology in rodent brain
(183) University of Pittsburgh3471 Fifth Avenue
Pittsburgh,PA15213 		25-0965591 501(c)(3) 73,086       Informing clinical decision making in the Pre- motor period of Parkinson disease (PD)
(184) University of Pittsburgh3501 Fifth Avenue 7039 BST3
Pittsburgh,PA15260 		25-0965591 501(c)(3) 250,000       Phenotypic Characterization of BAC LRRK2 Transgenic Rats in a rat model of Parkinson's disease
(185) University of Pittsburgh200 Lothrop Street
Pittsburgh,PA15213 		25-0965591 501(c)(3) 500,163       Developing An Alpha-Synuclein Imaging Agent Transgenic Rats treatment of L-DOPA-induced dyskinesias
(186) University of Rochester919 Westfall Road Building C Suit
Rochester,NY14618 		26-3800000 501(c)(3) 25,000       Langston Award 2011 transfer of alpha-synuclein
(187) University of Rochester265 Crittenden Blvd
Rochester,NY14620 		26-3800000 501(c)(3) 34,515       Transfer of DATATOP Samples a-synuclein model of PD: implications for the use of GDNF in neuroprotective therapy
(188) University of Rochester1351 Mt Hope Avenue Suite 216
Rochester,NY14620 		26-3800000 501(c)(3) 37,500       PPMI 2011 -- Three Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), A Parkinson's Progr Progression Markers Initiative (PPMI) Sub-study - Clinical Core funding
(189) University of Rochester919 Westfall Road Building C Suit
Rochester,NY14618 		26-3800000 501(c)(3) 55,688       PPMI Clinical Trial Site - SWEDD Amendment Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), A Parkinson's Progr Progression Markers Initiative (PPMI) Sub-study - Clinical Core funding
(190) University of Rochester1351 Mt Hope Avenue Suite 216
Rochester,NY14620 		26-3800000 501(c)(3) 79,285       PPMI 2011: Clinical Core Support for SWEDD and AV-133 Integration
(191) University of Rochester1351 Mt Hope Avenue Suite 216
Rochester,NY14620 		26-3800000 501(c)(3) 868,085       PPMI 2011: Year 2 Funding - Clinical Coordi Coordination Core
(192) University of South Florida4001 East Fletcher Avenue 6th Floo
Tampa,FL33613 		59-3102112 501(c)(3) 92,813       PPMI Clinical Trial Site - SWEDD Amendment Coordination Core administration
(193) University of South Florida4001 E Fletcher Ave MDC36
Tampa,FL33613 		59-3102112 501(c)(3) 250,000       Modulation of Microglial Activation. Progressive Rodent Model of Parkinson?s Disease
(194) University of Southern California1501 San Pablo St ZNI 111
Los Angeles,CA90033 		95-1642394 501(c)(3) 75,000       Use of HspB1 Chaperone to Inhibit Pathological alpha-Synuclein Aggregation
(195) University of Texas Medical Branch at Galveston301 University Blvd
Galveston,TX775551045 		74-6000949 501(c)(3) 75,000       Tau oligomers as a potential target for treatment of Parkinson`s disease
(196) University of Utah15 N 2030 E Rm 2350
Salt Lake City,UT841125330 		87-6000525 501(c)(3) 75,000       Development of dopaminergic cell line models of alpha synuclein expression for high-throughput drug screenings and monitoring of alpha synuclein expression
(197) University of Washington1660 S Columbian Way
Seattle,WA98108 		91-6001537 501(c)(3) 55,688       PPMI Clinical Trial Site - SWEDD Amendment of alpha synuclein expression for high-throughput drug screenings and monitoring of alpha synuclein expression
(198) University of Washington1705 NE Pacific St WH Foege Bui
Seattle,WA98195 		91-6001537 501(c)(3) 74,955       How does GBA1 dysfunction influence Parkinson's disease?
(199) University of Washington325 9th Avenue RM 303B RT Buildi
Seattle,MO98104 		91-6001537 501(c)(3) 150,000       Salivary Biomarkers for Parkinson's disease disease? Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup
(200) University of Washington325 9th Avenue RM 303B RT Buildi
Seattle,MO98104 		91-6001537 501(c)(3) 204,864       Using human cerebrospinal fluid samples collected in DATATOP study for biomarker validation in patients with Parkinson disease
(201) Van Andel Research Institute333 Bostwick Ave NE
Grand Rapids,MI49503 		52-2000823 501(c)(3) 400,000       Fasudil as a Novel Therapeutic for the Treatment of Parkinson's Disease validation in patients with Parkinson disease
(202) Vanderbilt University519 Light Hall
Nashville,TN37232 		62-0476822 501(c)(3) 74,999       Whole Exome Sequencing in an Amish Parkinson's Disease Pedigree
(203) Vanderbilt University23rd Avenue South at Pierce 417-D
Nashville,TN372326600 		62-0476822 501(c)(3) 315,000       Supplement to 'Discovery of mGluR4 Potentiators for Symptomatic and Disease-Modifying Treatment of PD
(204) Wadsworth Center Health Research Inc120 New Scotland Avenue PO Box 220
Albany,NY122012002 		14-1402155 501(c)(3) 75,000       Developing and characterizing anti-alpha- synuclein nanobodies from an immune phage display library clinical trial in PD patients
(205) Washington University in St Louis660 S Euclid Campus Box 8111
St Louis,MO63110 		43-0653611 501(c)(3) 50,000       Validation of Neuroimaging Biomarkers for Nigrostriatal Neurons- Supplement 2 display library
(206) Washington University in St Louis660 S Euclid Campus Box 8111
St Louis,MO63110 		43-0653611 501(c)(3) 353,565       Neurochemical Correlates of Cognitive Phenoty Phenotypes in PD
(207) Washington University in St Louis510 S Kingshighway Blvd
St Louis,MO63110 		43-0653611 501(c)(3) 500,000       Developing An Alpha-Synuclein Imaging Agent Phenotypes in PD
(208) WIL Research Laboratories1407 George Road
Ashland,OH448058946 		26-0564612 Public Sector 28,800       Collection and storage of rodent brain and peripheral tissues relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism
(209) WIL Research Laboratories1407 George Road
Ashland,OH448058946 		26-0564612 Public Sector 67,200       Collection and storage of rodent brain and peripheral tissues - LRRK2
(210) WIL Research Laboratories1407 George Road
Ashland,OH448058946 		26-0564612 Public Sector 207,000       Characterization Study -WIL Research Mouse and Rat Characterization-LRRK2 disease.
(211) WIL Research Laboratories1407 George Road
Ashland,OH448058946 		26-0564612 Public Sector 230,000       Characterization Study -WIL Research Mouse and Rat Characterization-ELAN
(212) Yale University230 South Frontage Road SHM I-269
New Haven,CT065208047 		06-0646973 501(c)(3) 74,165       Role of STriatal-Enriched protein tyrosine Phosphatase 61 (STEP61) in Parkinson's Disease
(213) Zenobia Therapeutics Inc505 Coast Blvd South Suite 111
La Jolla,CA92037 		26-2726709 Public Sector 300,000       Discovery of LRRK2 target engagement ligands to be used in imaging studies
2
Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................. Bullet Image
61
3
Enter total number of other organizations listed in the line 1 table ......................... . Bullet Image
41
For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 50055P
Schedule I (Form 990) 2011

Schedule I (Form 990) 2011
Page 2
Part III
Grants and Other Assistance to Individuals in the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 22.
Use Schedule I-1 (Form 990) if additional space is needed.
(a)Type of grant or assistance (b)Number of
recipients		 (c)Amount of
cash grant		 (d)Amount of
non-cash assistance		 (e)Method of valuation (book,
FMV, appraisal, other)		 (f)Description of non-cash assistance













Part IV
Supplemental Information. Complete this part to provide the information required in Part I, line 2, and any other additional information.
Identifier Return Reference Explanation
SCHEDULE I, PART I, LINE 2 PROCEDURES FOR MONITORING GRANT FUNDS IN THE UNITED STATES: THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THEYSCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.
Schedule I (Form 990) 2011


Additional Data


Software ID:  
Software Version:  


Schedule J
(Form 990)
Department of the Treasury
Internal Revenue Service
Compensation Information
For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet Complete if the organization answered "Yes" to Form 990,
Part IV, question 23.
SchJMediumBullet Attach to Form 990. SchJMediumBullet See separate instructions.
OMB No. 1545-0047
2011
Open to Public Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Part I
Questions Regarding Compensation
Yes
No
1a
Check the appropiate box(es) if the organization provided any of the following to or for a person listed in Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.
b
If any of the boxes in line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all the expenses described above? If "No," complete Part III to explain....
1b
 
 
2
Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
officers, directors, trustees, and the CEO/Executive Director, regarding the items checked in line 1a? ....
2
 
 
3
Indicate which, if any, of the following the organization uses to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.
4
During the year, did any person listed in Form 990, Part VII, Section A, line 1a with respect to the filing organization or a related organization:
a
Receive a severance payment or change-of-control payment? ...............
4a
 
No
b
Participate in, or receive payment from, a supplemental nonqualified retirement plan? ........
4b
 
No
c
Participate in, or receive payment from, an equity-based compensation arrangement? ........
4c
 
No
If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.
Only 501(c)(3) and 501(c)(4) organizations only must complete lines 5-9.
5
For persons listed in form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:
a
The organization? ...........................
5a
 
No
b
Any related organization? .........................
5b
 
No
If "Yes," to line 5a or 5b, describe in Part III.
6
For persons listed in form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:
a
The organization? ...........................
6a
 
No
b
Any related organization? .........................
6b
 
No
If "Yes," to line 6a or 6b, describe in Part III.
7
For persons listed in Form 990, Part VII, Section A, line 1a, did the organization provide any non-fixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............
7
 
No
8
Were any amounts reported in Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III .............................
8
 
No
9
If "Yes" to line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................
9
 
 
For Privacy Act and Paperwork Reduction Act Notice, see the Intructions for Form 990
Cat. No. 50053T
Schedule J (Form 990) 2011

Schedule J (Form 990) 2011
Page 2
Part II
Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.
For each individual whose compensation must be reported in Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.

Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and column (E) for that individual.
(A) Name (B) Breakdown of W-2 and/or 1099-MISC compensation (C) Retirement and other deferred compensation (D) Nontaxable
benefits		 (E) Total of columns
(B)(i)-(D) 		(F) Compensation
reported as deferred
in prior Form 990
(i) Base compensation (ii) Bonus & incentive compensation (iii) Other reportable compensation
(1) Katherine H Hood (i)
(ii)		 102,934
0 		173,750
0 		0
0 		0
0 		0
0 		276,684
0 		0
0
(2) Todd Sherer (i)
(ii)		 253,891
0 		135,000
0 		0
0 		7,350
0 		17,303
0 		413,544
0 		0
0
(3) Joanne Martz (i)
(ii)		 207,121
0 		72,000
0 		0
0 		7,350
0 		14,886
0 		301,357
0 		0
0
(4) Deborah W Brooks (i)
(ii)		 285,627
0 		188,750
0 		0
0 		7,350
0 		21,052
0 		502,779
0 		0
0
(5) Sohini Chowdhury (i)
(ii)		 178,726
0 		51,300
0 		0
0 		6,901
0 		6,808
0 		243,735
0 		0
0
(6) Sheila Kelly (i)
(ii)		 148,451
0 		19,500
0 		0
0 		5,039
0 		6,808
0 		179,798
0 		0
0
(7) Brian K Fiske (i)
(ii)		 160,649
0 		15,500
0 		0
0 		5,015
0 		14,886
0 		196,050
0 		0
0
(8) Mark A Frasier (i)
(ii)		 152,000
0 		16,750
0 		0
0 		0
0 		0
0 		168,750
0 		0
0








Schedule J (Form 990) 2011

Schedule J (Form 990) 2011
Page 3
Part III
Supplemental Information
Complete this part to provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4c, 5a, 5b, 6a, 6b, 7, and 8. Also complete this part for any additional information.
Identifier Return Reference Explanation
DETERMINATION OF COMPENSATION FOR OFFICERS SCHEDULE J, PART I, QUESTION 3 Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually.
Schedule J (Form 990) 2011

Additional Data


Software ID:  
Software Version:  
Schedule L
(Form 990 or 990-EZ)
Department of the Treasury
Internal Revenue Service
Transactions with Interested Persons
MediumBullet Complete if the organization answered
"Yes" on Form 990, Part IV, lines 25a, 25b, 26, 27, 28a, 28b, or 28c,
or Form 990-EZ, Part V lines 38a or 40b.
MediumBullet Attach to Form 990 or Form 990-EZ. MediumBulletSee separate instructions.
OMB No. 1545-0047
2011
Open to Public Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Part I
Excess Benefit Transactions (section 501(c)(3) and section 501 (c)(4) organizations only).
Complete if the organization answered "Yes" on Form 990, Part IV, line 25a or 25b, or Form 990-EZ, Part V, line 40b.
1(a) Name of disqualified person (b) Description of transaction (c) Corrected?
Yes No





2
Enter the amount of tax imposed on the organization managers or disqualified persons during the year under section 4958. ......................... Bullet Image$
 
3
Enter the amount of tax, if any, on line 2, above, reimbursed by the organization ....... Bullet Image$
 

Part II
Loans to and/or From Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 26, or Form 990-EZ, Part V, line 38a.
(a) Name of interested person and purpose (b) Loan to or from the organization? (c)Original principal amount (d)Balance due (e) In default? (f) Approved by board or committee? (g)Written agreement?
To From Yes No Yes No Yes No
Total ...............Small Bullet $  
Part III
Grants or Assistance Benefitting Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 27.
(a) Name of interested person (b)Relationship between interested person and the organization (c)Amount of grant or type of assistance
For Privacy Act and Paperwork Reduction Act Notice, see the
Instructions for Form 990 or 990-EZ.
Cat. No. 50056A
Schedule L (Form 990 or 990-EZ) 2011
Schedule L (Form 990 or 990-EZ) 2011
Page 2
Part IV
Business Transactions Involving Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 28a, 28b, or 28c.
(a) Name of interested person (b) Relationship between interested person and the organization (c) Amount of transaction (d) Description of transaction (e) Sharing of organization's revenues?
Yes No
(1) Donny Deutsch Board of Directors 47,586 Design and Creative Services   No
Part V
Supplemental Information
Complete this part to provide additional information for responses to questions on Schedule L (see instructions).
Identifier Return Reference Explanation
SCHEDULE L, PART IV BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS THE FOUNDATION INCURRED DESIGN AND CREATIVE ADVICE EXPENSES OF $47,586 FOR SERVICES RENDERED BY A COMMUNICATIONS, BRAND DEVELOPMENT AND DESIGN AGENCY, THE CHAIRMAN OF WHICH IS A FOUNDATION BOARD MEMBER.
Schedule L (Form 990 or 990-EZ) 2011

Additional Data


Software ID:  
Software Version:  




SCHEDULE M
(Form 990)

Department of the Treasury
Internal Revenue Service
NonCash Contributions
Right pointing arrow large imageComplete if the organization answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image Attach to Form 990.
OMB No. 1545-0047
2011
Open to Public Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Part I
Types of Property
(a)
Check if applicable 		(b)
Number of Contributions or items contributed 		(c)
Noncash contribution amounts reported on
Form 990, Part VIII, line 1g 		(d)
Method of determining
noncash contribution amounts
1 Art—Works of art ....        
2 Art—Historical treasures .        
3 Art—Fractional interests ..        
4 Books and publications ..      
5 Clothing and household
goods ....... 		     
6 Cars and other vehicles ..        
7 Boats and planes ....        
8 Intellectual property ...        
9 Securities—Publicly traded . X 43 28,138,747 FAIR VALUE
10 Securities—Closely held stock .        
11 Securities—Partnership, LLC,
or trust interests .... 		       
12 Securities—Miscellaneous ..        
13 Qualified conservation
contribution—Historic
structures ..... 		       
14 Qualified conservation
contribution—Other ... 		       
15 Real estate—Residential .        
16 Real estate—Commercial ..        
17 Real estate—Other ...        
18 Collectibles .....        
19 Food inventory ...        
20 Drugs and medical supplies .        
21 Taxidermy ......        
22 Historical artifacts ....        
23 Scientific specimens ..        
24 Archeological artifacts ...        
25 Other Right pointing arrow large image ( )
26 Other Right pointing arrow large image( )
27 Other Right pointing arrow large image( )
28 Other Right pointing arrow large image ( )
29
Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement ...
29
0
Yes
No
30a
During the year, did the organization receive by contribution any property reported in Part I, lines 1-28 that it
must hold for at least three years from the date of the initial contribution, and which is not required to be used
for exempt purposes for the entire holding period? ..................
30a
 
No
b
If "Yes," describe the arrangement in Part II.
31
Does the organization have a gift acceptance policy that requires the review of any non-standard contributions?
31
Yes
 
32a
Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash
contributions? ............................
32a
 
No
b
If "Yes," describe in Part II.
33
If the organization did not report revenues in column (c) for a type of property for which column (a) is checked,
describe in Part II.
For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 51227J
Schedule M (Form 990) 2011
Schedule M (Form 990) 2011
Page 2
Part II
Supplemental Information. Complete this part to provide the information required by Part I, lines 30b,
32b, and 33 and whether the organization is reporting in Part I, column (b) the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.
Identifier Return Reference Explanation
Schedule M (Form 990) 2011
Additional Data


Software ID:  
Software Version:  
SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service
Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or to provide any additional information.
MediumBullet Attach to Form 990 or 990-EZ.
OMB No. 1545-0047
2011
Open to Public
Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Identifier Return Reference Explanation
FORM 990, PAGE 1, LINE 1 AND PAGE 2, LINE 1   FINDING THE CURE FOR PARKINSONS TAKES AN ORGANIZATION WITH EXTRAORDINARY VISION. Actor Michael J. Fox established The Michael J. Fox Foundation for Parkinson's Research (the "Foundation"), incorporated in Delaware in 2000, after publicly disclosing in 1998 that he had been diagnosed with Parkinson's disease seven years earlier at age 29. In 2009, The Michael J. Fox Foundation for Parkinson's Research in Canada ("MJFF Canada") was established as an officially registered tax-exempt charity in Canada. As this entity meets the criteria for consolidation, its financial statements are consolidated with those of the Foundation. As MJFF Canada's assets and liabilities and its operations were not significant at December 31, 2011 and 2010, they are not shown separately in the accompanying consolidated financial statements. The Foundation is exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code, and from state and local taxes under comparable laws. MJFF Canada is exempt from similar taxes under Canadian law. Today, The Michael J. Fox Foundation is the world's largest private funder of Parkinson's research. It is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $288 million in research as of December 31, 2011, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. In addition to funding a broad portfolio of investigator-initiated and priority-driven research programs, the Foundation is working to transform the medical research enterprise and shape a system that fosters, rather than inhibits, the development of cures. MJFF partners with the Parkinson's research community, speeding financial and intellectual resources to the scientists who can help realize ideas with the greatest promise to impact patients' lives. The Foundation has ignited collaboration among academic and industry players by requiring researchers to share information in real time. To enable scientists to move toward breakthroughs faster, MJFF has stepped up to meet their need for research tools. To date, the Foundation has funded work on over 100 therapeutic targets, and is currently supporting over 20 clinical trials. Since its founding, MJFF has proven not only that a new kind of stakeholder can accelerate drug development - but that it is what was missing all along. While much has changed in the past decade, one thing remains constant: the Foundation's commitment o Parkinson's patients. Everything MJFF does is with patients in mind, at all stages of PD, which informs investments in disease-modifying therapies, better symptomatic treatments and new approaches to the symptoms entirely unaddressed by today's generation of drugs.
Form 990, Page 6 Governance, Management and Disclosure Line 2: TWO BOARD MEMBERS ARE MARRIED TO ONE ANOTHER. TWO BOARD MEMBERS ARE IN-LAWS. Line 11A: Process for Review of Form 990: The Finance Committee of the Board of Directors, in association with external auditors, approves the annual IRS Form 990 which is then made available to the entire Board before it is filed. Line 12A: Conflict of Interest Policy monitoring: Officers, directors and key employees complete a conflict of interest questionnaire annually. The information is reviewed by the Chief Financial and Administrative Officer, and conflicts are reviewed with the Board of Directors. Line 15: Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually. Line 19: Governing documents are available upon request. - Conflict of interest policy is available upon request. - Financial statements are available at www.michaeljfox.org.
Form 990, PAGE 12, LINE 5 OTHER CHANGES IN NET ASSETS OTHER CHANGES IN NET ASSETS IS ATTRIBUTABLE TO UNREALIZED LOSSES OF $10,721.
For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.
Cat. No. 51056K
Schedule O (Form 990 or 990-EZ) 2011

Additional Data


Software ID:  
Software Version:  
SCHEDULE R
(Form 990)
Department of the Treasury
Internal Revenue Service
Related Organizations and Unrelated Partnerships
MediumBulletComplete if the organization answered "Yes" to Form 990, Part IV, line 33, 34, 35, 36, or 37.
MediumBulletAttach to Form 990. MediumBullet See separate instructions.

OMB No. 1545-0047
2011
Open to Public Inspection
Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH
Employer identification number

13-4141945
Part I
Identification of Disregarded Entities (Complete if the organization answered "Yes" on Form 990, Part IV, line 33.)
(a)
Name, address, and EIN of disregarded entity


(b)
Primary activity


 		(c)
Legal domicile (state
or foreign country)

 		(d)
Total income
(e)
End-of-year assets


 		(f)
Direct controlling
entity

















Part II
Identification of Related Tax-Exempt Organizations (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.)
(a)
Name, address, and EIN of related organization


(b)
Primary activity


 		(c)
Legal domicile (state
or foreign country)

 		(d)
Exempt Code section
(e)
Public charity status
(if section 501(c)(3))

 		(f)
Direct controlling
entity

 		(g)
Section 512(b)(13) controlled organization
Yes No
(1) MJFF CANADA

365 Bay Street Suite 899
Toronto,Ontario  
CA
RESEARCH CA     MJFF (US)
 
 
 












For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 50135Y
Schedule R (Form 990) 2011
Schedule R (Form 990) 2011
Page 2
Part III
Identification of Related Organizations Taxable as a Partnership (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a partnership during the tax year.)
(a)
Name, address, and EIN of
related organization



 		(b)
Primary activity




 		(c)
Legal
domicile
(state or foreign
country)


 		(d)
Direct controlling
entity



 		(e)
Predominant income(related, unrelated, excluded from tax under sections 512-514)

(f)
Share of total income




 		(g)
Share of end-of-year
assets



 		(h)
Disproprtionate allocations?




 		(i)
Code V—UBI
amount in box 20 of
Schedule K-1
(Form 1065)
 		(j)
General or
managing
partner?



 		(k)
Percentage
ownership
Yes No Yes No












Part IV
Identification of Related Organizations Taxable as a Corporation or Trust (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.)
(a)
Name, address, and EIN of related organization



 		(b)
Primary activity



 		(c)
Legal domicile
(state or
foreign
country)
 		(d)
Direct controlling
entity


 		(e)
Type of entity
(C corp, S corp,
or trust)

 		(f)
Share of total income



 		(g)
Share of
end-of-year
assets

 		(h)
Percentage
ownership












Schedule R (Form 990) 2011
Schedule R (Form 990) 2011
Page 3
Part V
Transactions With Related Organizations (Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35, 35A, or 36.)
Note. Complete line 1 if any entity is listed in Parts II, III or IV.
Yes
No
1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?
a Receipt of (i) interest (ii) annuities (iii) royalties (iv) rent from a controlled entity . . . . . . . . . . . . . . . . . . . . . . .
1a
 
No
b Gift, grant, or capital contribution to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1b
 
No
c Gift, grant, or capital contribution from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1c
Yes
 
d Loans or loan guarantees to or for related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1d
 
No
e Loans or loan guarantees by related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1e
 
No
f Sale of assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1f
 
No
g Purchase of assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1g
 
No
h Exchange of assets with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1h
 
No
i Lease of facilities, equipment, or other assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1i
 
No
j Lease of facilities, equipment, or other assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . .
1j
 
No
k Performance of services or membership or fundraising solicitations for related organization(s) . . . . . . . . . . . . . . . . . . . .
1k
 
No
l Performance of services or membership or fundraising solicitations by related organization(s) . . . . . . . . . . . . . . . . . . . .
1l
 
No
m Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) . . . . . . . . . . . . . . . . . . . . .
1m
 
No
n Sharing of paid employees with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1n
 
No
o Reimbursement paid to related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1o
 
No
p Reimbursement paid by related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1p
 
No
q Other transfer of cash or property to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1q
 
No
r Other transfer of cash or property from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1r
 
No
2
If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.
(a)
Name of other organization 		(b)
Transaction
type(a-r) 		(c)
Amount involved 		(d)
Method of determining amount involved
(1) THE MICHAEL J FOX FOUNDATION (CANADA)

 C 2,277,800  
(1)
(2)
(3)
(4)
(5)
(6)
Schedule R (Form 990) 2011
Schedule R (Form 990) 2011
Page 4
Part VI
Unrelated Organizations Taxable as a Partnership (Complete if the organization answered "Yes" on Form 990, Part IV, line 37.)
Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.
(a)
Name, address, and EIN of entity 		(b)
Primary activity 		(c)
Legal domicile
(state or foreign
country) 		(d)
Predominant income(related, unrelated, excluded from tax under sections 512-514)

(e)
Are all
partners
section
501(c)(3)
organizations? 		(f)
Share of total income




 		(g)
Share of
end-of-year
assets 		(h)
Disproprtionate allocations? 		(i)
Code V—UBI
amount in box
20 of Schedule K-1
(Form 1065) 		(j)
General or
managing
partner? 		(k)
Percentage
ownership
Yes No Yes No Yes No






























Schedule R (Form 990) 2011
Schedule R (Form 990) 2011
Page 5
Part VII
Supplemental Information
Complete this part to provide additional information for responses to questions on Schedule R (see instructions).
Identifier Return Reference Explanation
Additional Data


Software ID:  
Software Version: